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BRE, brain and reproductive organ-expressed, is an anti-apoptotic protein, which 
was found over-expressed in human hepatocellular carcinoma (HCC). 
Over-expression of human BRE in mouse livers in a transgenic mouse model, 
TTR-V5-BRE, was demonstrated to attenuate the acute fulminant hepatitis induced 
by in vivo administration of agonistic anti-Fas antibody. By subcellular fractionation, 
BRE was found in the cytosol and nucleus. In the nucleus, BRE forms a heteromeric 
complex with multiple nuclear proteins, including BRCC36, BRCAl, BARDl, and 
some other DNA-repair proteins. The complex of BRE and BRCC36 was shown to 
potentiate the E3 ubiquitin ligase activity of the BRCAl/BARDl complex in vitro. 
Based on the above findings, two issues about BRE were addressed in this thesis: 1) 
the functional role of BRE in HCC; 2) the functional relationship between the 
nuclear and cytoplasmic BRE proteins 
HCC was chemically-induced in the transgenic (TTR-V5-BRE) and 
non-transgenic littermates by diethylnitrosamine (DEN). At 30 weeks after DEN 
injection, all male mice developed HCC. The transgenic mice (n=12), however, 
developed tumors twice as large as those of the non-transgenic littermate controls 
(n=8) (p=0.049, Exact Wilcoxon Rank Sum test). As to the numbers of tumor 
nodules in the livers between the 2 groups, there was no statistically significant 
difference. By contrast, female mice are known not as susceptible as the male mice to 
DEN-induce HCC. Here I observed only 8.3% of the female non-transgenic 
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littermates (n=12) developed DEN-induced HCCs, whereas 20% of the female 
transgenic mice (n=5) developed the carcinoma. For the paired tumoral and normal 
liver tissues, increased expression of the mouse endogenous BRE was detected in the 
former by Western blot analysis. This observation is comparable with the 
up-regulation of BRE in human HCC as reported before. I further demonstrated that 
DEN administration has no direct effect on BRE expression, as injection of the 
chemical did not result in any change in the protein expression level in the livers of 
15-day old infant mice or 6-8 weeks adult mice in at least the first week 
post-injection. As BRE is strongly expressed in lymphoid organs, lymphocytes could 
be highly positive in BRE expression. Although DEN-induced HCC is not associated 
with overt inflammation, the tumor site is often infiltrated by leukocytes to various 
extents. These leukocytes could conceivably contribute to the increased BRE 
expression found in the tumors. Immunohistochemitry staining of the DEN-induced 
tumors for CD45 (common leukocyte antigen) positive cells were therefore 
performed to relate the extent of leukocytic infiltration with BRE expression level of 
the tumors detected by Western blot. No statistically significant correlation between 
the extent of infiltration and the up-regulation of BRE was found. 
To address the relationship of the BRE proteins between the 2 cellular 
compartments, the protein was made visible under fluorescence microscopy by 
fusion to green fluorescent protein (GFP). A series of N- and C-terminal fusion 
protein constructs with different spacer length were generated. Unlike the fusion 
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between GFP and the EBV latent membrane protein 1 (LMP-1), all of the BRE-GFP 
constructs, except the ones with the longest spacer between GFP and BRE, named LI, 
expressed only weak fluorescence. To distinguish whether the diminished GFP 
fluorescence in the fusion was due to structural interference between the 2 protein 
partners, or an active function of BRE, constructs with deletion of the most highly 
conserved segment of BRE, which is most likely to result in disabling the function of 
the protein, were made and tested for GFP fluorescence in the fusion. No 
improvement in GFP fluorescence in the fusion with deletion mutants of BRE was 
found, indicating that the diminished GFP fluorescence in the fusion between GFP 
and BRE is likely an outcome of structural interference between the partners. 
Transfection of HeLa cells with the fusion constructs with visible fluorescence 
demonstrated that the proteins were localized in the cytoplasm and the nucleus, with 
the latter more prominently than the former. Upon overnight treatment with MG-132, 
a proteasome inhibitor, the fusion proteins were found concentrated in the nucleus. 
Aggregates in and around the nucleus were also observed. 
Taken together, these results suggest that BRE promotes growth, but not induction of 
hepatocellular carcinoma. If the GFP-BRE fusions reflect the native BRE protein, 
BRE protein resides mainly in the nucleus, and is prone to aggregate upon blockage 
of proteosomal degradation. 
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Chapter I Introduction 
1.1 Introduction of BRE 
l.l . lDiscovery of BRE 
BRE, Brain and Reproductive Organ-Expressed (NCBI GenelD 9577)，was first 
proposed to be a stress-responsive gene, as it was observed that the cellular transcript 
level of the gene declined following UV-irradiation. The gene was named BRE, 
because it was initially found most abundantly expressed in brain, ovary and testis by 
Northern blot analysis (Li et al., 1995). 
Subsequently, by yeast two-hybrid screen of a murine cerebellar cDNA library, 
BRE was identified as a cytoplasmic binding protein for the p55 receptor of 
TNF-a (TNFR-1). Follow-up experiments demonstrated that over-expression of BRE 
by transfection of the cDNA could down-modulate TNF-a-induced NF-KB 
activation. Thus, the protein was alternatively named as "TNFRSFIA modulator" 
(Gu et al” 1998). 
More recently, BRE was also localized in the nucleus (Dong et al., 2003; Li et 
al, 2004). By mass spectrometric analysis of proteins co-immunoprecipitated with a 
DNA repair protein, BRCAl-associated RING domain (BARDl) from cell lines, 
BRE was found to be a component of a nuclear holoenzyme complex, BRCC, which 
contains BRCAl, BARDl and other DNA repair and modifying proteins. Hence, 
BRE was also named as BRCC45 (Dong et al, 2003). The number 45 indicates the 
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approximate size of the protein identified in SDS-PAGE. 
1.1.2 Isoforms of BRE 
At least six transcript variants of human BRE can be generated through 
alternative splicing of the primary transcript. Three of them (aa, a b and ac) are 
produced by alternative splicing proximal to the 3' end of the transcript, resulting in 3 
protein isoforms with distinct C-termini. The other three (Pa, pb and pc) involve 
splicing in an additional exon between the canonical exon 1 and 2. The extra exon 
contains a strong translation initiator composed of an ATG triplet in Kozak consensus 
sequence context, and forms a short open-reading frame (ORF) which terminates just 
one nucleotide upstream of the canonical start codon. As it has been shown that a 
strong upstream initiator coupled with a short intercistronic length impedes 
translation reinitiation of the immediate downstream ORF，the p variants are unlikely 
to be ftmctional (Kozak, 1986; Kozak, 1987; Ching et al； 2001). Of these 6 
transcript variants, only oca (renamed subsequently by GenBank as transcript variant 
3) is predominantly expressed. Henceforth, BRE is referred to the protein isoform 
encoded by this predominant transcript aa. This major protein isoform is also 
designated by NCBI as isoform 2, although the isoform 1 designated by NCBI is in 
fact encoded by the least abundant transcript variant, a c (Ching et al,, 2001). The 
main BRE isoform is a 44kDa protein composed of 383 amino acids (Li et al., 1995). 
Its C-terminus is a tripeptide sequence, GKL, which is conserved in all sequenced 
vertebrate BRE, and fits the consensus sequence for peroxisome targeting signal 
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(Ching et al., 2001). However, localization of BRE in peroxisomes could not be 
experimentally verified by subcellular fractionation. Instead, BRE was found mainly 
in the cytosol with a minor fraction in the nucleus (Li et al., 2004). 
1.1.3 Homology and orthologs of BRE 
BRE has no primary protein sequence or domain homology with any other 
known protein sequences of the same organism (Ching et al., 2001). The closest 
match between BRE and any other protein is the stretch of N-terminal sequence from 
residue 37 to 86 which may have a tenuously weak homology with 
ubiquitin-conjugating enzymes (E2) at the E value of > 0.23. This value is well 
beyond the cutoff levels between 0.01 and 0.05, below which the match is considered 
significant (Pearson, 1996). Consequently, BRE is assigned a unique pfam domain, 
pfam06113. 
In contrast with the apparent lack of family member, BRE orthologs have been 
identified in a wide variety of organisms, ranging from animals to plants, suggesting 
that the origin of this gene can be dated back to the emergence of the eukaryotes 
more than 1.5 billion years ago. In plants, for example, high sequence homology to 
the E value of 2e-22 exists between human BRE and the ortholog in a common 
flowering plant, Arahidopsis thaliana (mouse-ear cress). Among the animal species, 
BRE orthologs have been found in insects, sea urchins and all fully-sequenced 
vertebrate genomes. Among the primates, BRE orthologs of human, chimpanzee, and 
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the new world primate, cotton-top tamarin, are completely identical. Even between 
the orthologs of human and mouse, which have diverged from each other 90 million 
years ago, the difference between the 2 proteins is limited to only 3 amino acids 
(Ching et aL, 2001). These findings suggest that BRE is an ancient protein playing an 
essential function since its advent in the single cellular ancestor of plants and animals. 
The lack of paralogs, i.e. homologous protein in the same organism, and its high 
conservation across a wide time span in evolution suggests that this protein may be 
the only surviving member of a very ancient protein family, which for some 
structural or functional reason has lost out in evolution. BRE may therefore be a 
living fossil protein playing a highly specialized function. 
1.1.4 Expression studies of BRE mRNA 
In primary fibroblasts, treatment with UV-irradiation or a DNA damaging agent, 
4-nitroquinoline-1 -oxide, resulted in decrease of BRE mRNA level. Decline of the 
transcript level could also be induced in brain glioma cell U-251 and the 
promyelocytic cell HL-60 by retinoic acid (RA), a cellular differentiating agent 
Interestingly, the more aggressive, X-ray resistant squamous carcinoma cell, 1483， 
was reported to express lower level of BRE transcripts compared with the less 
aggressive tumor lines. BRE transcript level was unchanged in lymphoblastoid cells 
after growth inhibition with MDC, which inhibits the activity of transglutaminase 
and arrests cells in late G1 phase (Li et aL, 1995). 
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In a later report, using in situ hybridization, BRE transcripts were strongly 
detected in the zona glomerulosa of the adrenal cortex, the glial and neuronal cells of 
the brain, as well as the round spermatids, Sertoli cells, and Leydig cells of the testis. 
Furthermore, BRE transcript levels in the zona glomerulosa and zona fasciculate of 
rat adrenal glands could be upregulated by nitrate and nitrite treatments. Finally, by 
multiple-tissue dot blotting, adrenal cortex and medulla were shown to express even 
higher levels of BRE transcripts than those of brain and reproductive tissues (Miao et 
a/., 2001). 
1.1.5 Expression and cellular localization of BRE protein 
With the advent of BRE-specific monoclonal antibodies, expression studies of 
BRE protein in cell lines and tissues were undertaken. By Western blot analysis, BRE 
protein was found expressed at comparable levels among all mammalian cell lines 
examined. These cell lines included Jurkat，KRC/Y, HeLa, HepG2, HL60, MCF7, 
NIH3T3, NSO and THP-1. By contrast, expression of BRE in different mouse organs 
was shown to vary considerably. Lungs and lymphoid organs showed the highest 
expression of BRE, whereas livers and hearts the lowest. Intermediate levels of the 
protein were found in the brains, testes and adrenal glands. Thus, in consistence with 
the above BRE transcript expression study，brain and reproductive organs are not 
where BRE is most abundantly expressed. Hence the name, BRE, is a misnomer for 
the gene and its encoded protein (Chan et aL, 2008). 
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By subcellular fractionation of lysates from cell lines, BRE was identified as 
mainly as a cytosolic protein. A minor fraction of BRE was detected in the nucleus. 
No localization of the protein in peroxisome, mitochondria, and the golgi was found. 
Furthermore, no translocation of BRE between the cytosolic and nuclear 
compartments during apoptotic induction was found. It suggested that the cytosolic 
and nuclear BRE proteins function independently (Li et aL, 2004). 
1.1.6 Interaction between BRE and death receptor 
As previously mentioned (1.1.1)，BRE was identified as a binding protein of 
TNF-Rl. It was shown by yeast two-hybrid assay that the cytoplasmic 
juxtamembrane domain of TNF-Rl was the binding target of BRE. In vivo binding of 
the two proteins was demonstrated by co-immunoprecipitation using mammalian cell 
lines co-transfected with the expression vectors for these 2 proteins. In the same 
yeast two-hybrid assay, binding between BRE and the cytoplasmic juxtamembrane 
domain of three other TNF receptor family members, Fas, TNFR2, and p75 
neurotrophin receptor was, however, not found (Gu et aL, 1998). 
The signaling proteins which interact with TNFR family members could be 
divided into two structural classes, containing either death domains (TRADD, FADD, 
and RIP) or TRAP domains (TRAFl, TRAF2 and TRAF3). Ligation of TNFRl, 
which contains death domains, can lead to downstream activation of nuclear factor 
kappa B (NF-KB), which is dependent on signal transduction through the adapter 
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protein TRADD (Hsu et al, 1996). NF-KB is a transcriptional factor whose activities 
can promote expression of anti-apoptotic genes, resulting in the inhibition of 
TNF-a-induced apoptosis (Gu et al, 1998; Meldrum et al, 2006; Gray-Schopfer et 
al., 2007). In the same study reporting the above yeast two-hybrid results, 
over-expression of BRE in cell lines by transfection was shown to down-regulate 
TNF-a-induced NF-KB activities as measured by gel shift assay and luciferase 
reporter gene system (Gu et al., 1998). The authors suggested that BRE would 
promote TNF-a-induced apoptosis. 
However, in a later study conducted in our laboratory using HeLa cells 
transfected with a V5-tagged BRE (GS-BRE) for immunoprecipitation experiments, 
endogenous TNF-Rl as well as Fas were found to be co-precipitated with GS-BRE. 
Furthermore, the GS-BRE transfected cells were more resistance to apoptosis 
induced by TNF-a and anti-Fas agonist antibody. These findings indicate that BRE is 
able to interact physically and functionally in vivo not only with TNF-Rl, but also 
Fas. Failure of the yeast two-hybrid assay in the previous report in identifying Fas as 
a binding partner of BRE thus represents a false negative result of the methodology. 
Moreover, the anti-apoptotic effect of BRE over-expression to TNF-a and Fas shown 
by our laboratory is in contrast with the previously predicted pro-apoptotic activity of 
the protein (Li et al., 2004). 
In the same report of our laboratory, molecular and functional activities of BRE 
7 
were further elucidated. Ligation of TNF and Fas receptors was shown to result in 
increased association of BRE with phosphorylated, sumoylated, and ubiquitinated 
proteins, although identities of these proteins remained unidentified (Li et al, 2004). 
This finding suggests that BRE could be involved in post-translational modification 
of proteins within or interacting with the death inducing signaling complex (DISC), a 
multi-protein signaling complex formed by members of the death receptor family 
upon apoptotic induction (Muzio et al,, 1996). Participation of BRE in DISC was 
shown by co-immunoprecipitation of tagged BRE with Fas and its characteristic 
DISC component, pro-caspase-8. Furthermore, rapid dissociation of the tagged BRE 
from TNF-Rl but not from Fas during apoptotic induction was observed (Li et al., 
2004). This observation is consistent with the then newly discovered phenomenon 
that, while the Fas-triggered DISC stays at plasma membrane, the membrane 
signaling complex triggered by activation of TNF-Rl is only transient and that the 
complex will progress into a cytosolic form. In the initial membrane form, the 
activated TNF-Rl forms complex with the signaling adaptor protein, TRADD，which 
in turn recruits RIP-1, TRAF2, and c-IAPl. This membrane complex form, known 
otherwise as Complex I, triggers activation of the pro-survival NF-KB pathway. 
Subsequently, this complex detaches from the membrane TNF-Rl to form a cytosolic 
complex with the pro-apoptotic signaling adaptor protein, FADD, which in turn 
recruits the apical pro-caspase-8, and starts the cascade of apoptosis. The cytosolic 
complex is known as Complex II (Micheau et al., 2003). The finding of our 
laboratory suggests that BRE has the propensity of binding to DISC, where the 
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protein acts to down-modulate the pro-apoptotic activity of the complex. 
1.1.7 Anti-apoptotic effect of BRE in cell line studies 
As mentioned above, the studies of our laboratory showed anti-apoptotic effect 
of BRE over-expression in cell lines against activation of death receptors, TNF-Rl 
and Fas. Further experiments demonstrated that the protective effect of BRE 
over-expression could be extended to non-death receptor-initiated apoptosis. 
It has been long been appreciated that cells can undergo extrinsic and intrinsic 
pathways of apoptosis, depending on how the programmed cell death is triggered. 
Cells receiving external signals through surface death receptors, such as the widely 
expressed TNF-Rl and Fas, undergo extrinsic pathway of apoptosis. Extrinsic 
apoptosis involves formation of DISC and activation of the apical caspase-8, which 
in turn starts an activation cascade of executioner caspases to dismantle the cell. In 
contrast, cells receiving stress signals, such as growth factor removal and DNA 
damage, undergo intrinsic pathway of apoptosis. Intrinsic apoptosis involves release 
of pro-apoptotic factors from the intermembrane compartment of mitochondria 
mediated by Bcl-2 family members, to trigger formation of apoptosome, in which 
another apical caspase 9 is activated. This is followed by cleavage and activation of 
downstream executioner caspases (Green et al., 1998; Gross et al., 1999; Wang, 
2001). Although cellular apoptosis can occur by either pathway independently, 
crosstalk between these two pathways can occur. Cleavage of a Bcl-2 family protein, 
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Bid, by caspase-8 activated in extrinsic apoptosis, can lead to mitochondrial release 
of cytochrome c and other pro-apoptotic factors, thus amplifying the destruction by 
extrinsic apoptosis. For some cell types known as CD95 type II cells, such as human 
colon cancer cell line, HCT116, human T leukemia Jurkat cell line, and primary 
hepatocytes, mitochondrial amplification of the death receptor-initiated apoptotic 
signal is even mandatory for the occurrence of apoptosis. Conversely, one of the 
pro-apoptotic factors released by mitochondria, Smac/DIABLO, is needed to 
promote activation of caspase-8 in the DISC generated by TNF-Rl activation (Deng 
et al； 2003). 
The work of our laboratory demonstrated that BRE over-expression led to 
inhibition of mitochondrial release of pro-apoptotic factors, regardless of whether the 
apoptosis was induced by activation of death receptors or stress stimuli. The 
inhibition was observed to occur downstream of Bid cleavage, and therefore closely 
proximal to mitochondrial outer membrane permeabilization. Interestingly, 
siRNA-mediated depletion of BRE attenuated apoptosis induced by the death 
receptor ligand, TNF-a, but not by the genotoxic stress stimulus, etoposide. This 
suggests that the physiological function of the death receptor-binding protein, BRE, 
is restricted to the inhibition of mitochondrial amplification of death 
receptor-mediated apoptosis. Over-expression of BRE in experimental or pathologic 
setting, however, leads further into inhibition of mitochondrial release of 
pro-apoptotic factors induced by stress stimuli (Li et al., 2004). 
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1.1.8 Anti-apoptotic effect of BRE in vivo 
As downregulation of apoptosis has been associated with neoplastic 
development (Zhivotovsky et aL, 2003), a well established mouse tumor model, 3LL 
Lewis lung carcinoma (Mandelboim et al., 1995), was employed to test for the effect 
of BRE over-expression by transfection. A 3LL Lewis lung carcinoma subclone, 
D122, was stably transfected with BRE cDNA and injected into the footpads of 
syngeneic immunocompetent C57BL/6 host and immunodeficent nude mice. Tumor 
growth rates of the transfected D122 were compared with those of the controls 
including untransfected parent clone and vector-alone transfectants. It was observed 
that the BRE-transfected D122 grew significantly faster as tumor mass than all of the 
controls. In cell culture condition, however, the BRE-transfected D122 did not show 
increased proliferation. These findings suggest that the enhancement of tumor growth 
by BRE over-expression is more likely due to the in vivo anti-apoptotic (i.e. 
pro-survival) effect of the protein than any effect on cell proliferation. In addition, as 
no significant difference in metastasis between the BRE-transfectants and controls 
was detected, BRE is not likely to be involved in cancer metastasis (Chan et al., 
2005). 
To test if BRE might have an in vivo anti-apoptotic role in normal tissue, a 
transgenic mouse model was generated, in which human BRE was specifically 
expressed in the mouse livers，which otherwise expressed little BRE. As no liver 
cancer was observed in the transgenic mice to as old as 16 months of age, 
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inordinately high expression of BRE alone is not sufficient to cause malignancy in 
the livers (Chan et al., 2008). The mice were then subjected to injection with agonist 
anti-Fas antibody to induce acute liver failure, a well-established in vivo apoptotic 
model (Ogasawara et al., 1993). Attenuation of Fas-induced hepatitis, as indicated by 
histology of the livers and significantly more transgenic mice than the non-transgenic 
littermates surviving the treatment, was found. This study has thus demonstrated 
clearly the anti-apoptotic effect of BRE over-expression in vivo (Chan et al., 2008). 
1.1.9 BRE's role in DNA repair and ubiquitination 
As mentioned in 1.1.1，BRE has been shown in a multiprotein complex in the 
nucleus known as BRCC. This complex was shown to display increased association 
with p53 as well as RAD51 following DNA-damaging treatments in vitro (Dong et 
al., 2003). As the complex was found to contain a multitude of DNA repair proteins 
including BRCAl and BARDl, it was proposed to be a DNA repair protein complex. 
BRCAl and BARDl heterdimer had earlier been discovered to have ubiquitin E3 
ligase activity (Hashizume et al., 2001). This activity was shown to be increased by 
the heterocomplex formed by BRE and BRCC36 in vitro (Dong et al., 2003); the 
effect of BRE alone, however, was not reported. More recently, BRCC36 has been 
paradoxically shown to be a deubiquitinase in vitro (Sobhian et al., 2007). 
Taken together this and the above findings, it appears that BRE is likely to have 
a role in regulating ubiquitination. In the same study, siRNA-mediated depletion of 
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BRE was shown to increase ionizing irradiation-induced cell death and disruption of 
the G2/M checkpoint arrest. Although it was not reported whether the increased cell 
death was apoptosis, the pro-survival effect of BRE shown is consistent to the 
anti-apoptotic role of the protein found by our laboratories (Li et al., 2004; Chan et 
al, 2005; Chan et al, 2008). 
1.1.10 BRE's role in regulation of Prohibitin and p53 expression 
Protein profiling by comparative proteomics of myoblasts C2C12 and Lewis 
lung carcinoma D122 depleted of BRE by siRNA or over-expressing BRE by 
transfection has been performed. On silencing of BRE by siRNA in C2C12 cells, 
up-regulation of Akt-3 and carbonic anhydrase III and down-regulation of the 26S 
proteasome regulatory subunit SI4, prohibitin and p53 were found (Tang et al, 
2006). 
Conversely, overexpression of BRE in D122 cells resulted in upregulation of 
p53 and prohibitin expression (Tang et al” 2006). In addition, 5 other proteins have 
been found up-regulated. These proteins are granulin precursor, TNF receptor 
associated factor 6, mitogen protein kinase 8, Mdm4 and Baculoviral lAP 
repeated-containing protein 4，the majority of which can target or crosstalk with NF-
KB, which in turn plays a central role in regulating cell proliferation, differentiation 
and survival (Tang et al, 2006). These data suggest that BRE plays multifunctional 
role in cellular stress response. 
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1.2 Hepatocellular carcinoma (HCC) 
1.2.1 Carcinogenesis 
Carcinogenesis develops through three separate sequential stages termed 
initiation, promotion, and progression (Pitot, 2001). 
A simple mutation in one or more cellular gene produced by agents would 
initiate carcinogenesis. In the stage of initiation, agents can alter the structure of 
DNA through various reactions: the formation of chemical adducts of DNA, mistakes 
in DNA repair, and oxidation of DNA bases (Pitot, 2001). 
The mutated cells may move into the stage of promotion via clonal replication 
of the initiated cells in the presence of a promoting agent from endogenous or 
exogenous sources (Pitot, 2001). Through replication, the cells transmit the mutated 
message to the progeny (Fausto et aL, 1999). The character of promotion is its 
reversibility on withdrawal of the promoting agents. 
Once established by an irreversible transition from the stage of promotion to 
progression, it would increase aggressiveness of the tumor (Pitot, 2001). Further 
development of the mutations leads to the malignancy finally. 
1.2.2 Diethylnitrosamine -induced HCC 
HCC is the third largest cause of cancer deaths world wide, particularly in 
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Africa and Asia. Viral hepatitis, alcohol liver disease, and carcinogen exposure are 
the major causes (Bruix et al., 2004). 
Diethylnitrosamine (DEN) is a common carcinogen for the livers. It is a 
complete genotoxic carcinogen, which can induce liver tumors without any 
promoting agents, particularly in neonatal mice, whose proliferating hepatocytes are 
particularly susceptible to it (Bai et al., 2005). Tumors of the livers, kidneys, and 
lungs have been induced in rats by the feeding of DEN (Herrold et al,, 1963). 
DEN-induced liver carcinogenesis is likely initiated by formation of 
promutagenic adducts in the DNA of hepatocytes in the first 2 days after 
administration of DEN (Dyroff et al., 1986). Conversion of DNA adducts into 
mutations in daughter cells could be resulted from the subsequent marked 
enhancement of cell replication, despite the rapid ability of cellular DNA repair 
mechanism to resolve most of adducted sites (Columbano et al, 1981). Thus, cell 
proliferation is thought to play an important role in the initiation of 
chemically-induced HCC (Columbano et al, 1981). Unlike the livers of the neonatal 
mice, the rate of cell turnover in mature livers is extremely low. In the absence of 
compensatory proliferation, DEN-exposed hepatocytes of adult mice do not yield 
genetically transformed progeny (Maeda et aL, 2005). These mutations would 
eventually lead to oncogenic transformation and tumor development. Indeed, after a 
single injection of neonatal mice with DEN, adenomas and carcinomas can be 
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developed from the mutated cells caused by the carcinogen (Verna et al., 1996). 
It has been shown that hepatocytes-specific deletion of IKKp, which prevents 
NF-KB activation (Maeda et al.’ 2005), increased DEN-induced HCC. Absence of 
NF-KB activation was demonstrated to correlate with enhanced reactive oxygen 
species (ROS) production, increased JNK activation, and hepatocyte death. Death of 
hepatocytes in conjunction with the release of IL-6, a hepatomitogen, by Kupffer 
cells under inflammatory condition triggered compensatory proliferation of the 
surviving hepatocytes, thus fixing DNA mutations into progeny cells. 
Anti-inflammatory intervention targeting Kupffer cells has therefore been proposed 
in chemoprevention of HCC. Conversely, chemicals or viruses that interfere with 
NF-KB activation in hepatocytes have been suggested to promote HCC development 
(Maeda et al, 2005). 
1.2.3 Mouse model for HCC studies 
Genetically altered mice offer different ways to dissect genetic pathways in the 
carcinogenesis. Genes associated with HCC could be divided into two groups: those 
that augment spontaneous HCC and those that increase susceptibility to chemically 
induced HCC. HCC develops spontaneously in transgenic mice over-expressing 
HBV surface antigen (HBsAg) and the hepatomitogen transforming growth factor a 
(TGFa) (Fausto et al., 1999). However, unlike HBsAg or TGFa transgenic mice, 
hepatocyte-specific BRE transgenic mice were not found to develop HCC 
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spontaneously by as old as 16 months of age (Chan et al., 2008). 
1.2.4 BRE in human HCC 
Over-expression of BRE has been observed in human HCC, with the expression 
levels in positive correlation with histological grades of the cancer (Chan et al.’ 
2008). However, whether this association between BRE over-expression and HCC 
represents just an epiphenomenon or importantly a functional relationship was 
unclear. In this study, I chemically induced HCC in the liver-specific BRE transgenic 
mice and the wildtype littermates by using DEN. The objective was to find out 
whether over-expression of BRE in the hepatocytes would have any functional effect 
on HCC development. 
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1.3 Green Fluorescent Protein (GFP) 
Green fluorescent protein (GFP), which weights 29 kDa, was first cloned from 
jellyfish Aequorea Victoria (Cubitt et al,’ 1995). 
Enhanced green fluorescent protein has been optimized for brighter 
fluorescence when excitation maximum is 488 nm and emission maximum is 507 
nm. 
1.3.1 Application of GFP in biological research 
GFP has been used in numerous applications: as a reporter molecule to study 
gene expression, and protein trafficking and localization (Chalfie et al., 1994), as a 
marker for transfection (Lamm et al” 1997); or to follow morphological changes of 
apoptotic cells (Li et al, 1997; Strebel et al., 2001). GFP fusion with the protein of 
interest, which can be visualized by fluorescence microscopy, allows for the 
determination of subcellular localization, mobility and transport pathways of the 
protein, and even its interactions with other proteins at single molecule level in living 
cells (Chalfie, 1994; Haraguchi, 2002). 
1.3.2 Advantage of GFP applied in protein localization 
Subcellular localization of the protein of interest can often reveal important 
aspects of the protein function. Different members of the same structural family can 
reside in the same or quite different compartments, depending on whether their 
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functions overlap or are distinct (Koroleva et al, 2005). 
To characterize protein localization, immunostaining technique has been a 
traditional method. However, fixation and staining steps could lead to misleading 
results. By tagging proteins with GFP, localization and trafficking of the proteins in 
living cells can be directly monitored. GFP has thus been proved invaluable as an in 
vivo marker for subcellular localization of proteins under study (Chalfie et al, 1994). 
In this study, I used GFP as a tag to visualize BRE protein in the cells. Both 
pEGFP-C 1 and pEGFP-N3 expression vectors, which allow fusion of BRE at the C-
and N-terminus of GFP, respectively, were employed. As a control, the Epstein - Barr 
virus latent membrane protein 1 (LMP-1), which shares a similar molecular weight 
as BRE protein, was cloned into pEGFP-Cl vector. The objective was to identify the 
subcellular localization of BRE without the confounding process of fixation. 
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Chapter II Materials and Methods 
2.1 Materials 
2.1.1 Primers used for cloning 
All primers were purchased from Invitrogen. 
Name of Primers Sequence of Primer 
LMPH3 5’ CGAAGCTTCGATGGAACGCGACCTTGAGA 3, 
LMPBamS 5 ’ CGGGATCCGCGTCATAGTAGCTTAGCTGAACTGGG 3 ’ 
GS5 5' CGGGATCCATGTCCCCAGAAGTG 3， 
GS3 5' CGGGATCCAAGGCACAGTCGTGG 3’ 
BreCHindm 5' CCCAAGCTTCGTCCCCAGAAGTGGC 3' 
Bre383BamH I 5' CGGGATCCGAGCTTTCCATTGGC 3， 
N3BGLII 5' CCCAGATCTATGTCCCCAGAAGTGGGC 3’ 
BreS'NHindm 5' CCCAAGCTTATGTCCCCAGAAGTGGC 3， 
N3HIND m 5，CCAAGCTTCCAGCTT TCCATTGGC 3 ’ 
Bre603 5 ‘ TATGTGCAGTTTAAATCG 3 ‘ 
Bre875 5' GGAGAAGATGCTGAA 3' 
60LINK87 5 ’ CGATTTAAACTGCACATAGGAGAAGATGCTGAA 3 ’ 
Bre883 5' TCCAAAGATAAAATCCG 3， 
Bre 114 5' TTACTTGTGGTGAAGG 3‘ 
88LINK114 5' CCGATTTTATCTTTGGATTACTTGTGGTGAAGG 3' 
5' AGC TTCAGG TGG TGG CGG TTC AGG CGG AGG TGG 
ScFv Linker up 
CTC TGG CGG TGG CGG ATC GCA 3’ 
5' AGCT TGC GAT CCG CCA CCG CCA GAG CCA CCT 
ScFv Linker low 
CCG CCT GAA CCG CCA CCA CCTGA 3’ 
Note: Cloning sites were showed in underlined letters. 
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Hindm： AAGCTT: BamH I : GGATCC: Bgl II: AGATCT. 
2.1.2 DNA clones used in the studies 
GS-BRE: GS-BRE (ResGen GeneStorm® Clone for accession L38616, 
commercially available from Invitrogen, is a pcDNA3.1-based expression vector for 
the main BRE isoform fused at the C-terminus of the encoding protein with V5 and 
6x His tags. (Fig 2.1) 
pEGFP-Cl: GeiiBank Accession #: U55763, from Invirtogen (catalog #6084-1). 
pEGFP-Cl encodes a enhanced green fluorescence protein. Genes cloned into the 
vector will be expressed as fusions to the C-terminus of EGFP. (Fig 2.2) 
pEGFP-N3: GenBank Accession #: U57609, from Invirtogen (catalog #6080-1). 
pEGFP-N3 encodes a enhanced green fluorescence protein. Genes cloned into the 





































Figure 2.1 cDNA and amino acid sequence of GS-BRE 
(Unigene Cluster ID HS.80426, Invitrogen ). 
A) cDNA sequence of GS-BRE; B) amino acid sequence of GS-BRE. The amino 
acid sequence of GS-BRE predicts a protein of 416 amino acids with a V5 epitope 
and a 6x Histidine tag at the C-terminus. Sequence of V5 epitope is shown in 
underlined bold letter. Sequence of 6xHis is shown in underlined italic letters. 
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Figure 2.2 Map of pEGFP-Cl vector 
pEGFP-Cl encodes an enhanced green fluorescence protein. Genes cloned into the 
vector will be expressed as fusions to the C-terminus of EGFP. 
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Figure 2.3 Map ofpEGFP-N3 vector 
pEGFP-N3 encodes an enhanced green fluorescence protein. Genes cloned into the 
vector will be expressed as fusions to the N-terminus of EGFP. 
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2.1.3 Materials for DNA manipulation 
Chemicals and Enzymes Manufacturers 
dNTPs Amersham (Buckinghamshire HP79NA) 
Restriction enzymes 
T4 DNA ligase New England Biolab (Beverly, MA) 
T4 DNA ligase buffer 
AmpliTaq Gold™ DNA ploymerase 
lOX PGR buffer Applied Biosystems (Branchburg, NJ) 
MgCb Solution (25mM) 
DNA MW marker 1KB Plus ladder Invitrogen (Carlasbad, CA) 
Agarose Sigma (St.Louis, MO) 
2.1.4 Materials for protein manipulation 
Materials Manuufacturers 
LumingenfM ECL Plus Amersham (Buckinghamshire HP7 9NA) 
X-ray film FUJIFILM (Tokyo, Japan) 
Protease Inhibitor Cocktail Sigma (St. Louis, MO) 
PVDF membrane PALL (East Hills, NY) 
Prestained protein molecular weight standards Invitrogen (Carlsbad, CA) 
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2.1.5 Antibodies 
Antibodies Manufacturers Clone # 
Anti- mouse Fas Upstate (Charlottescille, VA) CHI 1 
Biotinylated anti-mouse CD45 
R&D systems (Minneapolis, MN) 30-Fl 1 
antibody 
Anti-V5 Invitrogen (Carlsbad, CA) -
Anti-BRE monoclonal antibody CIU，CUHK #489-7 
Anti-LMP monoclonal antibody CIU, CUHK ^ 
Immunology Consultants 
Rabbit anti-GFP polyclonal antibody 9-2005 
Laboratory (Newberg, OR) 
Anti-GAPDH monoclonal antibody^US-Biological (Swampscott, MA) GH-140-11 
Anti-mouse Ig-HRP BD Pharmingen (San Diego, CA) 554002 
Anti-Rabbit Ig-HRP Promega (Madison, WI) W 4 0 1 B ^ 
Streptavidin-HRP BD Pharmingen (San Diego, C A ) -
2.1.6 Chemicals 
Chemicals Manufacturers 
Diethylnitrosamine (DEN) Sigma (St. Louis, MO) 




Annexin V-PE Apoptosis detection kit BD Pharmingen (San Diego, CA) 
BCA protein assay kit Pierce (Rockford, IL) 
BigDye® Terminator v3.1 Cycle Sequencing Kit Applied Bio systems (Branchburg, NJ) 
Plasmid miniprep Kits 
QIAquick gel extraction kit Qiagen Inc. (QIAGEN GmbH, Hilden) 
Plasmid midiprep Kits 
2.1.8 Culture media and reagents 
Products Manufacturers 
DMEM — 
Fetal Bovine Serum 
GIBCO BRL Life Technologies (Gaithersburg, MD) 
Trypsin-EDTA 
Penicillin/Steptomycin 
Lipofectamine iM 2000 Invitrogen (Carlsbad, CA) 





Thermal Cyclers PTC-200 MJ research, Inc (South San Francisco, CA) 
Autosequencer ABI-3100 Applied Biosystems (Providence, RI) 
FAScan Calibur Becton Dickinson (Franklin Lakes, NJ) 
Ultra Microplate Reader Bio-Tek Instruments Inc. (Winooski, VT) 
Pathcentre Tissue Processor 
SHANDON (Waltham, MA) 
Finesse 325 microtome 
Axioplan2 imaging microscopy 
Carl Zeiss (Thornwood, NY ) 
Confocal Laser Scanning Microscopy 
Densitometer 700 
BIO-RAD Laboratories (Hercules, CA) 
BIO-RAD Semi-Dry Transfer Cell 
2.1.11 Animals 
Mouse Strain Service Provider 
C57BL/6 LASEC Research Unit, CUHK 
TTR-V5-BRE C57BL/6 Breed with wildtype female C57BL/6 
BALB/C LASEC Research Unit, CUHK 
2.1.12 Slides 
Type of slides Manufacturers 
Teflon printed diagnostic 12 wells slide Immuno-Cell Int., Belgium 
SuperFrost® Plus MENZEL-GLASEL, Germany 
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2.2 Methods 
2.2.1 Construction of Plasmids 
2.2.1.1 Polymerase chain reaction (PCR) 
PGR for full-length human BRE 
Full-length human BRE with or without V5 tag were cloned into different cloning 
sites of pEGFP-Cl or pEGFP-N3 vector, in order to generate different BRE-EGFP 
fused protein. PCR were performed in the standard methodology. Specific primers 
were designed and all primers were synthesized by Invitrogen. 
PCR for truncated fragments of BRE 
By using GSB plasmid as template, BRE fragments of position 1-60 and 89-383 
were amplified by PCR using primer pairs GS5/ Bre603 and Bre875/Bre383 
respectively. The two fragments were then purified by gel electrophoresis and then 
linked together by PCR using a mixture of primers containing 60LINK87, GS5 and 
Bre383. The PCR product was a truncated BRE fragment (BREA61-86) with 
nucleotide residue 61 to 86 being deleted. The gel purified product was then cut by 
EcoRI and BamHI and then ligated to EcoRI and BamHI cut vector. Positive clones 
were then subjected to sequencing for confirmation. 
The same strategy was used for generating another truncated BRE clones 
(BREA89-114, with residue 89 to 114 being deleted). Primer pair GS5 and Bre883 
for amplification of BRE fragment of residue 1 to 88; primers Brel 14 and 
Bre383BamHI for amplification of BRE fragment of residue 115 to 383; and primers 
GS5, Bre383BamHI and 88LINK114 for ligation of the two fragments. 
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2.2.1.2 Enzyme Digestion and Ligation 
PCR products were separated by agarose gel electrophoresis. The gel purified products 
were digested with enzyme according to cloning sites and directly ligated into 
pEGFP-Cl or pEGFP-N3 vectors at 16�C for overnight. 
2.2.1.3 Transformation 
2.2.1.3.1 Preparation of competent cells 
0.5 ml of Top 10 bacteria overnight culture was added into 50ml of LB broth 
medium. Bacteria were incubated at 37 °C 250 rpm until OD6oo=0.4. The cells 
were by collected the culture in 50 ml tube by centrifuging at 2500 rpm at 4°C for 15 
min. Pellet was washed once in 25 ml of ice-cold 100 mM CaC^. Pellet was spinned 
down again and resuspended in 25 ml of ice-cold 100 mM CaCl� and incubated on 
ice for overnight. Cells were collected by centrifuging and resuspended in 5 ml of 
ice-cold glycerol contained CaC^. 50 p,! of cells suspension was aliquated in ice-cold 
eppendorf tubes. The cells then were used for transformation or kept at -80°C. 
2.2.1.3.2 Heat-shock Transformation 
Ligation product (3 was added into each tube contained 50 [il of competent cells 
and incubated on ice for 15 minutes. The tube was incubated in 42°C water bath for 
30 seconds. The tube was incubated back on ice for 10 minutes. 0.8 ml of LB broth 
medium was added to the cells and cells were incubated at 37°C 250 rpm for half an 
hour. 100 [i\ of cells were used for plating. Plate was incubated at 37°C for 
overnight. 
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2.2.1.4 Midi Prep ofplasmids 
A single colony of bacteria was picked to grow in 100 ml of LB medium contained 
30|j.g/ml Kanamycin at 37°C 250 rpm overnight. The extraction process was 
performed according to the manufacturer's manuals. 
The concentration of DNA were measured with NANODrop and confirmed by 
running agarose gel. 
2.2.2 Cell Culture 
HeLa (Human cervical carcinoma) (ATCC #CCL-2) 
Cells were grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented 
with 10% Fetal Bovine Serum (FBS) and lOOU/ml of Penicillin and streptomycin. 
Cultures were maintained at 37°C with 5% CO2. 
2.2.3 Transfection 
24-well format: 
8x104 cells were seeded in one well of 24-well plate one day before transfection. 
After overnight incubation, cells were approximately 80-90% confluent. Culture 
medium was changed to 500 of Dulbecco's Modified Eagle's Medium (DMEM) 
without antibiotics or serum. 2 |ig of DNA was diluted into 50 |il of DMEM without 
antibiotics or serum. The tube was mixed gently. 2 of Lipofectamine 2000 
( I n v i t r o g e n i M ) was diluted into 50 of DMEM without antibiotics or serum. The 
diluted DNA was combined with diluted Lipofectamine 2000, and the complex was 
vortexed for 5 seconds. Incubate for 20 minutes at room temperature. The 100 |il of 
DNA-lipid complexes were added to each well containing cells and medium. Cells 
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were incubated before a gentle mix. After 4-6 hours, medium contained DNA-lipid 
complexes were changed with serum and antibiotics contained fresh medium. Assays 
were performed at 48-72 hours after transfection. 
6-well format: 
The procedure of transfection on 6-well is similar with above 24-well format. The 
three differences are a: 4x10^ cells were seeded one day before transfection; b: 
plating medium was 2 ml instead of 500 |il; c: More DNA-lipid complexes were 
formed: 8 ).ig of DNA and 8 ofDMEM were used in total volume of 500 fal. 
GFP-BRE expression study: 
1.5 i-ig of the constructs DNA together with 0.5 |ag of GSB was co-transfected into 
HeLa cells in 24-well plate format. Transfection protocol was according to the 
manufacturer's instruction. Flow cytometry assay and Western blot analysis were 
performed at 48 hr post-transfection. 
2.2.4 MG-132 treatment 
GFP-BRE fusion constructs were transfected into HeLa cells using the above 
protocol in 24-well format. 24 hours after transfection, 4000 cells in 100 [i\ of 
medium were seed onto one well of the 12-well slide. After attachment for several 
hours, 5 ^iM MG-132 was added to cells and DMSO was added as a control. 
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2.2.5 Flow Cytometry 
Ten thousands cells from each FACS tube were acquired on a FASC Calibur (Becton 
Disckson) and analyzed using CELLQuest software (Becton Disckson). GFP signals 
were acquired on the FL-1 channel using log amplification. 
For GFP fluorescence, the markers in the control histogram were set at the 95%. That 
brighter than 95% cells of untransfected HeLa cells were counted. The same marker 
set in the control histograms was used for the histograms of treated cells. 
2.2.6 Western blotting 
2.2.6.1 SDS-PAGE 
Samples were resolved on 10% sulphate-polyacrylamide gel. Electrophoresis was 
carried out at room temperature at lOOV, The gel was calibrated with Prestained 
Protein Marker (Invitrogen). After electrophoresis, proteins were transferred onto 
PVDF membrane (PALL) using a Semi-Dry transferring cell (Bio-Rad) at 20V for 
30 min. 
2.2.6.2 Immunoblotting 
Nonspecific binding sites of the PVDF membranes containing the transferred 
proteins were blocked by 5% non-fat milk in TBS for 1 hour at room temperature. 
Primary antibody was then added to the membrane in the following dilution: 
Anti-BRE (Homemade, culture supernatant) 1:1 diluted in 2.5% BSA in TBS 
Anti-GFP (Immunology Consultant Laboratory) 1:3000 diluted in 5% non-fat milk in 
TBS 
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After overnight incubation at room temperature with shaking, the membrane was 
subsequently washed with TBS for 3 times at 10 minutes each. The bound primary 
antibody was visualized with appropriate HRP-conjugated secondary antibody in 
dilution of 1:3000 for 2 hours. 
Lumingen detection reagent (ECL Plus, Amersham) was added to the membrane and 
membrane was then exposed to X-ray film. 
2.2.7 Production of Monoclonal antibody 
The immunogen for raise anti-BRE antibody was a polypeptide of human BRE from 
residues 40 to 225 fused at the C-terminus with a 12-mer LMPl epitope sequence. 
There are only 2 amino acids differences between the human and mouse in this 
stretch of BRE polypeptide. Clone#246-26 and #489-7 were successfully generated 
by Dr. Ben Chan. Clone# 246-26 and # 489-7 anti-BRE hybridoma cells were grown 
in DMEM supplemented with HT medium. Culture supernatant was collected for 
Western blotting and immunohistochemisty. 
3 3 
2.2.8 Mice handling 
TTR-V5-BRE transgenic mouse strain was generated by Dr. Arthur Ching. The 
coding region for the full-length BRE with a C-terminal V5 tag was cloned into the 
unique StuI site of a liver-specific transthyretin (TTR) promoter fragment-containing 
expression vector (TTR exV3). 
Male transgenic mice which phenotype showed positive were crossed with 8-
week-old widetype female C57BL/6. The offspring were given 5 mg/kg of DEN 
intraperitoneally at 15-day of age. Sexing and genotyping were performed at 30-day. 
30 weeks after DEN injection, mice were sacrificed to determine tumor incidence 
and size, livers were 10% neutral buffered formalin fixed and paraffin embedded. 
Surface liver tumors of each mouse were scored visually and the maximal tumor size 
of each mouse was measured after fixation with formalin. The tumor nodules with 
middle size (plane area around 5-10 mm^) and non-tumoral tissue were collected for 
Western blot analysis; or tumors (ST, MT, BT) were collected according to the tumor 
size. 
All animals were obtained from and housed in the Laboratory Animal Services 
Centre of the Chinese University of Hong Kong. The experimentation has been 
approved by the Animal Research Ethics Committee of the Chinese University of 
Hong Kong. 
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2.2.9 Tissue Processing 
Tissue processing was performed with SHADON Pathcentre. The program setting 
showed below: 
70% Ethanol Ihr 
70% Ethanol Ihr 
95% Ethanol Ihr 
95% Ethanol Ihr 
100% Ethanol Ihr 
100% Ethanol 1.5hr 








2.2.10 Tissue section 




Formalin-fixed and paraffin embedded sections were dewaxed in xylene and 
rehydrated in a graded series of ethanol. 1% H2O2 in ddH20 was applied for blocking 
activities of endogenous peroxidase for 5 minutes. Antigen retrieval was performed 
in pH6.0 Citrate Buffer at 60°C water bath for 40 minutes. After the treatment with 
blocking solution (2.5 % bovine serum albumin in PBS), appropriate primary 
antibody was applied and incubated for overnight at 4°C. Slides were washed with 
PBS and biotinylated secondary antibody was added in 1:500 dilution. After 30 
minutes incubation, slides were wash with PBS. Then a streptavidin-horseradish 
peroxidase conjugate was added and signals were visualized with 0.03% 
diaminbenzidine (DAB). Mayer hematoxylin was used for counterstaining. Slides 
were dehydrated in alcohol, cleared in xylene and mounted in DPX. 
2.2.12 Hematoxylin and Eosin stain 
Formalin-fixed and paraffin embedded sections were dewaxed in xylene and 
rehydrated in a graded series of ethanol. Slides were washed briefly in distilled water. 
Sections were stained in Harris hematoxylin solution for 8 minutes. Sections were 
washed in running tap water for 5 minutes. Sections were differentiated in 1% acid 
alcohol for 5 seconds. Sections were washed running tap water for 1 minute. Sections 
were stain in Eosin Yellowish solution for 30 seconds to 1 minute. Sections were 
dehydrated through 95% alcohol, 2 changes of absolute alcohol for 15 minutes each. 
Sections were clear in 2 changes of xylene for 15 minutes each. Slides were mount 
with xylene based mounting medium DPX. 
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2.2.13 Images Capture 
Pictures were captured with Carl Zesis Axioplan2 microscopy and Spot Advanced 
software in Lee Hysan Lab. 
2.2.14 Confocal Imaging 
Confocal images were scanned by Carl Zeiss Confocal microscopy. The excitation 
source was an argon laser (wavelength 488 nm, laser energy 10%.)- The emission 
wavelength was 510-515 nm. 
2.2.15 Statistical Analysis 
SPSS 12.0 (Release 12.0; SPSS, Chicago, Illinois) for Windows was used for all 
statistical analysis. Data were presented as means 士 SD for normal distributed 
variables or median 士 250/<) quartile for skewed variables. Mann Whitney U test and 
Exact Wilcoxon Rank Sum test were used to compare non-parametric variables 
between two groups. Kruskal-Wallis Test was used to test the differences among 
non-parametric independent variables in 3 groups. 
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Chapter I I I BRE promotes growth of chemically-induced hepatocellular 
carcinoma 
3.1 DEN induced HCC in male mice 
It has been established that a single DEN injection to 15-day-old mice can 
induce hepatocellular carcinoma (HCC), which models human HCC (Verna et al, 
1996; Maeda et al, 2005). To determine the role of BRE in HCC, TTR-V5-BRE 
transgenic mice and non-transgenic littermates at 15-day-old were injected with DEN 
intraperitoneally. In the TTR-V5-BRE transgenic mouse, expression of the 
transgenic human BRE was controlled by a transthyretin (TTR) promoter fragment, 
which has been shown to drive high levels of liver-specific transgene expression 
(Yan et al., 1990). TTR-V5-BRE transgenic mice, thus, was a suitable animal model 
for liver cancer. 
All of the male mice developed HCC at 30 weeks post injection. Surface tumors 
were counted after fixation with formalin (Table 3.1). The numbers of visible HCCs 
(>0.5mm) were not significantly different between both non-transgenic and 
transgenic mice (Figure 3.1). 
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Table 3.1 Tumor number of DEN-treated male mice 
Non-transgenic male mice Transgenic male mice 
n=8 r ^ 
Mouse# Tumor# Mouse# Tumor# 
6872 9 6869 4 
4939 16 6868 5 
4972 18 6827 15 
4946 25 4948 16 
4981 31 6867 20 
4949 34 4944 26 
4995 37 6871 30 
4973 43 3998 42 
4997 43 
4000 59 
4 9 ^ 6 4 
Mann Whitney U test, p=0.792 
(Difference between two groups was not statistically significant.) 
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Non-trsnsgenic mice Transgenic mice 
Figure 3.1 Tumor numbers of the transgenic and non-transgenic groups 
Tumor number in livers (tumor size >0.5 mm) of male TTR-V5-BRE transgenic (n = 
12) and non-transgenic mice (n = 8) at 30weeks after DEN (5 mg/kg per body weight) 
injection. Data were showed in box plots. 
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The maximal tumor size was defined as the square root of the product of the 
longest diameter and its perpendicular diameters of the largest tumor in the livers 
(Aoki et al., 1994). Median maximal tumor size for the TTR-V5-BRE transgenic 
mice was nearly 2-fold larger (5.7) than their littermates (2.73), and the difference 
was statistically significant (Table3.2, Figure 3.2.). 
None of the non-transgenic and transgenic mice which developed HCCs showed 
metastasis in other organs at 8 months post-injection. 
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Table 3.2 Maximal tumor size of DEN-treated male mice (diameter of tumor) 
Non-transgenic male mice Transgenic male mice 
n=12 
Mouse# Maximal Size (mm) Mouse# Maximal Size (mm) 
4939 1.41 6827 1.73 
4946 1.73 4997 2 
4972 1.73 4948 2.5 
4973 2 6868 2.74 
4949 3.46 6869 4 
4995 3.87 6867 4.47 
6872 4.9 4000 6.93 





p=0.049, Exact Wilcoxon Rank Sum test 








1 5.。。- i 一 
. i — 
2 0.00-
1 1 
No门-trsinsgenic Mice Transgenic Mice 
Figure 3.2 Maximal tumor sizes of two groups 
The maximal tumor size was defined as the square root of the product of the longest 
diameter and its perpendicular diameters of the largest tumor in the livers. Data were 
showed in box plots. * p<0.05. 
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3.2 BRE facilitates HCC in female mice 
Female C57BL/6 mice are known to be less sensitive to DEN-treated 
carcinogenesis. In female mice's group, estrogen would inhibit the secretion of IL-6 
from Kupffer cells exposed to necrotic hepatocytes and thereby reduce circulating 
concentration of IL-6 (Prieto et aL, 2008). As expected, only 8.3% of the female 
non-transgenic littermates (n=12) developed DEN-induced HCCs. However, the 
incidence of tumor formation for the female transgenic mice (n=5) increased to 20% 
(Figure 3.3). As the sample sizes were too small at this stage of the work, no 
statistical statement can be made about the significance of the present difference 
shown by these 2 groups. 
30. 00% 
8 20% 
= 2 0 . 00% - • 
10.00% - 8.30% ^ ^ H • • 
0 . 0 0 % - I ^ 1 ^ 
Non-transgenic mice Transgenic mice 
Figure 3.3 Incidence of HCCs (>0.5 mm) in female mice. 
Incidence of HCCs in female non-transgenic (n = 12, 8.3%) and TTR-V5-BRE 
transgenic (n = 5，20%) mice at 8 months after DEN (5 mg/kg.BW) injection. 
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3.3 Over-expression of BRE in tumor portion 
Dramatic over-expression of BRE has been observed in human HCC, with 
the expression levels in positive correlation with histological grades of the cancer 
(Chan et al； 2008). To study BRE expression in DEN-induced HCC, Western blot 
analysis was performed on the tumor and its adjacent normal tissue for BRE 
expression. The liver of transgenic mouse could express both transgenic human 
BRE proteins and endogenous mouse BRE proteins, with different protein size. 
The transgenic human BRE was tagged with a V5 epitope. The paired liver 
extracts were probed by the anti-BRE monoclonal antibody #489-7 (Chan et al., 
2008). Up-regulation of the endogenous BRE in the tumor portion compared with 
the adjacent normal tissue of livers was detected (Figure 3.4). 
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Figure 3.4 BRE expressions in 30 weeks DEN-induced HCCs 
Western blot: tumoral and adjacent normal liver extracts of DEN-treated male 
mice (Eight non-transgenic mice; twelve transgenic mice.) at 30 weeks 
post-injection. 
Equal amount of proteins (50)ig of proteins, measured with BCA kit) were 
separated by 10% SDS-PAGE and BRE protein level was detected using 
anti-BRE monoclonal antibody. The protein amount of loading was normalized by 
GAPDH protein. 
N: adjacent normal part of liver, T: tumoral part of liver, (at early stage of 
experiment, tumors with median size were harvested, similar with MT.) ST: small 
tumor, MT: median tumor, BT: big tumor, *: mistake in sample collection. 
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3.4 Direct effect of DEN on BRE expression 
The stage model, initiation together with promotion and progression, has 
usually been employed to explain tumorigenesis (Pitot，2001). According to the 
model, initiation results from a simple mutation in one or more cellular gene 
controlling key regulating pathways of the cells. The mutated cells then undergo 
tumor promotion through enhancement of cellular proliferation by the continuous 
exposure the promoting agents, which could be from either endogenous or 
exogenous sources (Pitot, 2001). Finally, the progression stage defines 
development of the tumor into carcinoma through additional mutations of the 
basically unstable karyotype (Pitot, 2001; Lim et al., 2002). 
The chemical DEN is known to form chemical adducts of DNA or errors in 
DNA repair to initiate the mutation of cells. The overall reactions after initiation 
are similar to those of inflammation and repetitious degradation of hepatocytes 
(Lim et al., 2002). In this initiation stage induced by DEN, expression of BRE 
protein was investigated by Western blot analysis. 
To investigate the direct effect of DEN on BRE expression, DEN was 
administered to adult C57BL/6 mice at the dosage of 5 mg/kg BW, and BRE 
expression in the liver was analysis by Western blot within one week after 
injection. No up-regulation of BRE expression was observed compared with the 
PBS control mice at 4, 8 and 24 hr or 3，7 days after injection (Figure 3.5A，B). 
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This investigation was extended to 15-day-old mice. Similar with previous results 
of adult mice, no difference between PBS-treated and DEN-treated groups was 
found (Figure 3.5C). 
The immediate effects of DEN on up-regulation of BRE proteins could be 
ruled out based on the results of Western blot. However, the long-term inferences 
of DEN were unknown. 
4 6 
A) 




PBS DEN Day1 PBS DEN Day3 PBS DEN Day? TG 
_ — I I I Jii. . J g L J g * 一 GAPDH 
C) 
TG PBS DEN 6hr DEN Day1 PBS DEN Day3 DEN Day6 
^mmm 绘•电、发 . ^ t ^ ^ m m — Transgenic BRE 
I l"" . I . , . i l l . . . . � . t i l . n _ i . n i i J m I ： — Endogenous BRE 
— GAPDH 
Figure 3.5 BRE expressions in short-term DEN-treated mice. 
A) Adult C57BL/6 male mice were treated with PBS or DEN (5 mg/kg). At 4hr, 
8hr, 24hr post-injection, mice were sacrificed, and livers extracts were collected 
for Western blot analysis. 
B) Adult C57BL/6 male mice were treated with PBS or DEN (5 mg/kg). At dayl, 
day3, day? post-injection, mice were sacrificed, and livers collected for Western 
blot analysis. 
C) 15-day-old mice were treated with PBS or DEN (5 mg/kg). At 6hr, dayl, day3, 
day6 post-injection, mice were sacrificed, and livers collected for Western blot 
analysis. 
Notes: 
PBS: PBS-injected mice, DEN: DEN-injected mice, TG: Transgenic mice, as a 
positive control for detecting BRE protein. 
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3.5 Contribution of infiltrating cells in up-regulation of BRE 
Previous report reveals that BRE is highly expressed in lymphoid organs, 
such as spleen and thymus, suggesting lymphocytes may be BRE-positive (Chan 
et al, 2008). As DEN-induced HCC is often accompanied by various degrees of 
leukocytic infiltration, contribution of these infiltrating cells to the observation of 
BRE protein up-regulation in the liver tumors was studied using common 
leukocyte antigen CD45 in immunohistochemistry. 
CD45 positive cells were often present in tumor nodules but barely 
detectable in the non-tumor portion. The levels of CD45-positive cell infiltration 
were graded from 1 to 3 as defined in the legend of Table 3.3. The 
immunohistochemical staining patterns corresponding to the 3 grades are also 
shown in Figure 3.7. No difference in the extent of BRE upregulation among 
tumors of different levels of infiltration was found (Table 3.3，Figure 3.6). 
CD-45 positive cells were estimated by the numbers of positive cells in each 
high power field in the previous reports (Zhang et aL, 2005; Bao et al., 2007). 
However, to study the contribution of infiltration in the up-regulation of BRE 
expression in tumor nodules, the infiltrating cells in the tumors should be scored 
and graded. Among different grade of infiltration, the ratios of up-regulation of 
BRE expressions were compared. 
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Table 3.3 Degrees of infiltration and up-regulation of BRE protein 
^ ^ I n f i l t r a t i o n U p r e g u i a t i �二 f 
Endogenous BRE 
6869* 1 0.84 
4995 1 2.2 
6868* 1 1.02 
4972 1 1.68 
4949 1 1.83 
6867* 1 1.85 
4947* 1 6.53 
6827* 2 1.12 
6871* 2 1.47 
4939 2 1.79 
4971* 2 12.51 
3998* 2 3.15 
6872 2 0.65 
4997* 3 0.98 
4946 3 2.23 
4944* 3 8.07 
4000* 3 8.18 
4973 3 2.24 
4948* 3 4.8 
4981 3 4.23 
Notes: 
Upregulation of Endogenous BRE: Intensities of Western blot bands were 
measured by BIO-RAD DENSIMETER. Intensities of endogenous BRE were 
normalized by those of GAPDH protein. Data here are the ratios of tumoral parts 
over adjacent normal parts. 
The infiltrating cells in a middle-sized tumor nodule (area around 5-10 mm^, 
which typically represented the tumor tissues in the Western blot analysis) were 
counted. Based on the counts, the extent of infiltration was graded from 1 to 3: 
1 = No or only scattered small infiltration 
2 = Presence of small clusters, each containing 30 - 50 infiltrating cells 
3 = Presence of larger clusters, each containing more than 50 infiltrating cells 
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Figure 3.6 Distribution of BRE up-regulation in DEN-induced HCC in each 
of the 3 levels of leukocytic infiltration 
Kruskal-Wallis Test, p=0.201. Data showed in the figure were the median of 3 
groups respectively. 
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Lack of statistical difference in BRE upregulation among tumors of different 
levels of CD45-positive cell infiltration indicates that the presence of the infiltrating 
leukocytes was not the main factor in accounting for the increased BRE protein 
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Figure 3.7 CD45 staining on liver sections of DEN-treated mice 
A) Mice #6867，grade of infiltration: 1; scattered small infiltration. 
B) Mice #6872, grade of infiltration: 2. Arrows showed the small clusters. 
C) Mice #4981，grade of infiltration: 3. Arrows showed the large clusters. 
Scale bar = 50 |am. Manification of main figure and small figure were 200X and SOX, 
respectivly. 
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Chapter IV Subcellular localization of BRE 
Immunostaining is a typical technique to detect the localization of proteins by 
using a specific antibody. However, in the case of localization of BRE, low purity of 
our homemade anti-BRE monoclonal antibodies limits the application of 
immunostaining. Reporter proteins, such as green fluorescent protein (Chalfie, 1994), 
may offer an alternative to antibodies for determing the subcellular localization of 
BRE. The GFP was applied in the study by fused it to BRE. 
Both pEGFP-C 1 and pEGFP-N3 expression vectors were employed in this 
study to visualize the localization of BRE protein. pEGFP-Cl and pEGFP-N3 are 
commercial available from Invitrogen. Both of them encode the enhanced green 
fluorescent protein. Through insert the interested gene into pEGFP-Cl and 
pEGFP-N3, the encoded proteins were fused at the C-terminus and N-terminus of 
GFP respectively. 
However, in the preliminary experiment, GFP-BRE fusion through HindlH and 
BamH I of the vector, resulting in a spacer between GFP and BRE protein of 8 
amino acids long, generated a substantially 5 fold weaker green fluorescence 
compared with the likewise fusion of GFP and LMP1, the EB virus latent membrane 
protein 1, and nearly 20 fold weaker than the GFP control. The reasons for the 
diminished GFP fluorescence upon fusion with BRE were investigated herein. Two 
possibilities were addressed: 1) Protein folding of BRE might interfere with correct 
folding of the fusion partner, GFP; and 2) BRE might post-translationally modify 
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GFP, as BRE has been previously found to associate with phosphorylated, 
sumoylated, and ubiquitinated proteins, and with BRCC36 to potentiate the E3 ligase 
activity of BARDl-BRCAl complex (Li et al.’ 2004). 
4.1 GFP-BRE fusion constructs 
To address the first possibility that BRE might interfere with correct folding of 
GFP in the fusion protein, a series of N- and C-terminally fusion constructs with 
different spacer length were generated. These different space lengths were created by 
either inserting the BRE cDNA at different restriction sites of the multiple cloning 
site (MCS) region of the GFP fusion vector, or by inserting a single or multiple 
copies of single chain Fv linker (Trinh et al., 2004) in MCS between BRE and GFP 
coding regions. The amino acids of the linker were (GGGGS)3. The lengths of 
spacers of these constructs are shown in Table 4.1. Some of the constructs also have 
a short sequence, V5 epitope, fused to the C-terminus of BRE. The schematic 
structures of GFP-BRE fusions were showed in Table 4.2. 
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Table 4.1 Description of GFP fusion constructs. 
Protein Spacer length 
Construct Name Size (number of Remark 
(kPa) amino acids) 
Cloned into pEGFPCl vector 
pGFPCl-LMPl 70.4 8 
pGFPCl-BRE 71.5 8 
pGFPC 1-BREV5 75.1 8 with V5 epitope at C-terminal 
pGFPCl-BRE383 72.5 22 
pGFPC 1-GSB6 76.1 22 with V5 epitope at C-terminal 
pGFPCl-BRE L4 72.7 28 one ScFv linker 
pGFPCl-BRELl 73.9 46 double ScFv linkers 
Cloned into pEGFPN3 vector 
pGFPN3-BRE 70.8 5 
pGFPN3-BRE2 72 18 
pGFPN3-BREL 73.2 36 one ScFv linker 
5 6 
Table 4.2 The schematic structures of GFP-BRE and control fusion proteins 
Name Abbr. Schematic Structure 
pGFPCl GFP [洛靜、 1 
pGFPCl-LMPl LMPl ^ M i i i i 彳彳; 
spacer 
pEGFPCl-BRE CI ^ 
p 腿 C1-BREV5 C1V5 
p E G F P C 1 - G S 6 — : m - ^ ^ M H 
P 腿 CI 棚 3 3S3 
ScFv Linker 
pEGFPCl-BREL4 L4 I _ _ _ _ _ _ _ 
pEGFPCl-BRELl LI 
— 穩 NB 
p 腿 N3-B 腿 NB2 
— 穩 L | N B L 
Notes: ^ H - m l l i M Green Fluorescent Protein, weight about 29kDa 
^ ^ ^ ^ ^ ^ H B R E protein, weight about 42.5kDa 
V5 tag 
；丨丨丨：丨；丨丨丨；脳卿丨;：丨：丨丨丨丨I 
Latent membrane protein 1, weight about 41kDa 
57 
4.1.1 Transfection of GFP-BRE fusions 
The low fluorescent signals of CI, which were obtained in preliminary results, 
may due to the transfection efficiencies of the constructs. Thus, the GFP-BRE fusion 
constructs were co-transfected with GeneStorm (GSB), which expressed the full 
length of BRE protein with a V5 epitope and 6xhis tag at the C-terminus, and 
weighted around 49 kDa. 
Before transfection, concentration of Plasmid DNA was confirmed by running 
agarose gel (Figure 4.1). 
r" Lo 
CL Q_ > CD ^ CM - J 
LL 3 T- ？- CO G cn CD CD 广 寸 
^ ^ B Z S B S B 
Figure 4.1 Amounts of plasmid DNA 
0.5 |_ig of DNA was cut with HindlH and 0.25 of the digested products were 
loaded to run agarose gel. 
5 8 
4.1.2 Flow cytometry analysis of GFP-BRE fusion 
By flow cytometry, intensities of green fluoresence and GFP-positive cells can 
be quantified. Compared to the GFP and LMPl control transfected cells, the 
GFP-BRE fusions all generated weaker fluorescence. Among all nine BRE fusions, 
the L4 and LI , which contained 1 and 2 ScFv linkers, respectively, between the two 
proteins, appeared the 2 brightest fusions. 
The four C-terminally fused BRE fusions, CI, C1V5, GS6 and 383, behaved 
nearly the same features: around 30 FLl (green channel) signals of the geometric 
median of range Ml，the proportions of GFP-positive cells were less than the LMPl 
and GFP controls. 
The fusions with BRE as the N-terminal partner were also less flouresecent than 
those with the protein fused at the other end of GFP. Presence of the 
translation-promoting Kozak consensus at the initiation of GFP but not of BRE could 
account for the discrepancy in fluorescence between the N- and C-terminal fusions. 
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Figure 4.2 Flow cytometry assay of GFP-BRE fusions 
Notes: GFP-BRE fusion transfected cells 
Untransfected cells 
Flow figures of GFP-BRE fusion transfected cells were overlay with those of 
untransfected HeLa cells. Percentage showed indicated the proportion of 
GFP-positive cells among the transfecetd cells. Range Ml was set for that 5% of 
cells reflected the GFP-positive cells. The marked heights indicated the Geometric 
mean of the intensities in range Ml . The intensity was quantified as this Geo mean. 
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Differential Intensities of GFP-Positive Cells 
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Names of the fusions 
Figure 4.3 Differential intensities of fusions 
Figure showed the quantification of green fluorescent signals of GFP-positive cells in 
at least three independent experiments. Data showed mean 土 SD. 
Note: Neg-ctrl was the untransfected HeLa cells. Range Ml was set, in which 5% of 
untransfected HeLa cells reflected the GFP-positive cells. 
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4.1.3 Western blot Analysis of GFP-BRE Fusion. 
Western blot analysis was performed at 48 hr post-transfection to show the 
expression of GFP-BRE fusions, using both of anti-BRE and anti-GFP antibodies. 
Anti-BRE monoclonal antibodies could recognize endogenous BRE, the 
co-transfected GSB protein and the GFP-BRE fusions. Though the six C-terminal 
fusions (CI, C1V5, GS6, 383，LI and L4) expressed similar protein levels in Figure 
4.4A，which was probed by anti-BRE antibody, LI appeared the highest expression 
among the six fusions in Figure 4.4B. Showing in Western blot analysis probed by 
anti-GFP antibody, LMPl fusion expressed higher than the GFP-BRE fusions, and 
LI as well as L4 were the two fusions with highest expression. 
In the lanes of LI and L4 (Figure.4.4B)，the fusions contained the ScFv linker 
between GFP and BRE protein, proteins weighted around 30kDa were probed with 
anti-GFP antibody. As GFP weights 29kDa, the proteins may be truncated from the 
fusion protein. 
GFP-BRE fusions revealed similar expression levels when probed by anti-BRE 
antibody, whereas differential expressions were observed when probed by anti-GFP 
antibody. It may due to the saturation of anti-BRE monoclonal antibody, which 
resulted in no difference among fusion expressions. 
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Figure 4.4 Western blot analysis of GFP-BRE fusion proteins 
1.5 \ig of constructs DNA and 0.5 jag of GSB were transfected into HeLa cells. At 48 
hours after transfection, cells were harvested and lysed with lysis buffer. 30 |ag of 
protein lysate were separated by 10% SDS-PAGE. Equal loading amount of proteins 
were normalized by GAPDH protein. Upper panel (A) was performed using 
anti-BRE monoclonal antibody. Lower panel (B) was performed using anti-GFP 
polyclonal antibody. Asterisk indicated the non-specific bands caused by the 
polyclonal antibody. 
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4.1.4 Stability of GFP-BRE fusion proteins 
To quantify the expression of fusion proteins, bands of Western blot were 
scanned with densitometer. Differential expression levels of fusion proteins were 
observed. 
Expression of fusion (detected by anti-BRE antibody) 
V) A t-
c 1.5 1 
I I I i i I L l u i 
I I I 0 ] — - T — 1 ——1——^ 1 — — ^ 1 ^ 1 “ 1 ^ 1 ^ 1 
C1 C1V5 GS6 383 L1 L4 NB NB2 NBLL 
Name of fusions 
Expression of fusions (detected by anti-GFP antibody) 
•E 2.5 1 
• 
I 1.5 • I • 
I - I I I I I I I I 
LMP1 C1 C1V5 GS6 383 L1 L4 NB NB2 NBLL 
Name of fusions 
Figure 4.5 Densities of bands in Western blot of the fusions 
Western blot bands were scanned by BIO-RAD densitometer. The density of GSB 
protein was normalized by GAPDH protein. Western blot were performed using 
anti-BRE antibody in upper figure, anti-GFP antibody in lower figure. 
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Anti-BRE monoclonal antibodies could recognize endogenous BRE, the 
co-transfected GSB protein and the GFP-BRE fusions. However, unlike the two 
controls, GFP and LMPl, the GSB protein displayed different degrees of 
suppression. 
Expression of GSB protein in co-transfectd cells 
m 8 丁 
C/5 7 — • 
§ J I 
昏姿 4 - - • I 
i i M , l l , i . | l , 
^ 0 … 显 + 量 1 • I • I • I • I • - 1 
Name of fusions 
Figure 4.6 Expression of GSB proteins in fusions co-transfected cells 
Bands of GSB proteins were scanned with BIO-RAD densitometer. The density of 
GSB protein was normalized by GAPDH protein. 
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4.2 Fusions between GFP and the deletion mutants of BRE 
By comparing the protein-coding sequences of all the available BRE orthologs, 
10 amino acid residues in the N-terminal half of BRE are completely conserved in all 
the othologs from human to plant. The sequence segment from residue 61 to 86 
contains 5 out of the 10 amino acids, suggesting this 26-amino-acids region is 
playing an essential role for the protein. Another segment from 89-114 just 3 amino 
acids downstream contains 3 other such completely conserved residues. The cysteine 
at residue position 112 may be analogous to the active cysteine of 
ubiquitin-conjugating enzyme E2. This is consistent with the report that BRE may be 
involved in regulating ubiquitination (Dong et al., 2003; Li et al., 2004). Thus, 
deletion of either segment is likely to disable functions of the protein. Deletion 
mutants lacking either segment 61-86, or 89-114 were generated and fused with GFP 
at either ends. Their unmutated counterparts were 383 (CA61, CA89) and NB (NA61, 
NA89), respectively. This set of fusion constructs was to test whether the effect of 
BRE on diminishing the fluorescence of its fusion partner, GFP, was dependent on its 
functions. If it was, the fluorescence of GFP would be restored. If the effect of BRE 
on GFP was the result of structural interference, disabling BRE functions would not 
improve GFP fluorescence. The details of mutants are shown in Table 4.3. 
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Table 4.3 The schematic structures of deleted mutants. 
Abbr； 
Name of the mutants Schematic s t r u c t u r e 
pEGFPCl-A61BRE CA61 | | 4 |削瞧睡 
pEGFPCl-A89BRE CA89 [ Q f p | ~ [ " A 8 9 B R E — 
pEGFPN3-A61BRE NA61 111 G F P 
III R N n r IT I T rr I M L X、. 
pEGFPN3-A89BRE NA89 A 8 9 B R l ^ t 键糊 
IllilhUHdilj^ 
Note: mTTNI^ f M l the segment from 61 to 86 of BRE was deleted. 
A 8 9 B R E the segment from 89 to 114 of BRE was deleted. 
Green Fluorescent Protein. 
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4.2.1 Transfection of mutants 
Normalization of DNA amounts was confirmed by running agarose gel. 
O ^ O ^ 一 —> 
Figure 4.7 DNA amounts of mutants 
0.5 \jLg of DNA was cut with Hindlll and 0.25 |ag of the digested products were 
loaded to run agarose gel. 
According to the confirmed concentration, the 4 mutants were transfected into 
HeLa cells. 
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4.2.2 Low expression of mutants 
Fusion constructs of the BRE mutants and GS-BRE were co-transfected into 
HeLa. Flow cytometry assay and Western blot analysis were performed at 48 hr post 
transfection (Figure 4.8, Figure 4.10). 
Figures of flow cytometry analysis have clearly shown that mutation of BRE 
did not lead to brighter fluorescence of the fusion constructs (Figure 4.8). This 
finding appeared not to support the possibility that the diminished GFP fluorescence 
in the GFP-BRE fusions could be the outcome of an active function of BRE 
modifying the GFP partner. However, it is possible that these mutations which 
inevitably distorted the structure of BRE could lead to instability of the entire 
constructs, masking any improvement of GFP fluorescence. 
Exceptionally low expression of CA89 and NA89, compared with the unmutated 
counterparts, 383 and NB, respectively, in Western blot analysis (Figure 4.10), 
indicates that deletion of segment from 89-114 could indeed lead to instability of the 
entire constructs. The comparatively lower, but still considerable, expression CA61 
compared with 383, and very low expression ofNA61, also indicates that deletion of 
segment 61-86 could destabilize the fusion constructs, though not as critically as the 
deletion of 89-114. The lack of improvement of GFP fluorescence shown by CA61 
maintaining a considerable protein expression level also argues against an active 
functional of BRE in down-modulating the fluorescence of the GFP partner protein 
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Figure 4.8 Flow cytometry assay of the four mutants 
Note: Treated cells 
Untreated cells 
Figures of GFP-BRE fusion transfected cells were overlay with those of 
untransfected HeLa cells. Percentage showed indicated the proportion of 
GFP-positive cells among the transfecetd cells. The marked heights indicated the 
Geometric mean of the intensities in range Ml . 
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Intensities of the mutant fusions 
广 。 [ _ 一 — — — —一 
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！ 100 m ——一_ 
0 L •- 二一 ‘ I r - ^ I r ^ I T � 
Neg-ctl GFP LMPl CA61 CA89 NA61 NA89 
Names of fusion proteins 
Figure 4.9 Intensities of GFP-positive cells in mutants 
Figure showed the quantification of green fluorescent signals of GFP-positive cells in 
at least three independent experiments. Data showed mean 士SD. 
Note: Neg-ctrl was the untransfected HeLa cells. Range Ml was set, in which 5% of 
untransfected HeLa cells reflected the negative cells. 
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Figure 4.10 Western blot analysis of the four mutants. 
1.5 |Lig of constructs DNA and 0.5 \xg of GSB were transfected into HeLa cells. At 48 
hours after transfection, cells were harvested and lysed with lysis buffer. Western blot 
analysis in the upper panel was performed using anti-BRE monoclonal antibody. 
Western blot analysis in the lower panel was performed using anti-GFP polyclonal 
antibody. Equal loading amount of proteins were normalized by GAPDH protein. 
Asterisk indicated the non-specific bands due to the polyclonal antibody. 
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Figure 4.11 Densities of bands in Western blot of the fusions 
Western blot bands were scanned with BIO-RAD densitometer. The density of GSB 
protein was normalized by GAPDH protein. 
Upper panel (A): Western blot was performed using anti-GFP antibody. 
Lower panel (B): Western blot was performed using anti-BRE antibody. 
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4.3 MG-132 treatments 
The data above suggest that fusion of BRE with GFP results in an unstable 
protein product. To verify that, MG-132 was used to inhibit the proteasomal 
degradation system and the BRE-GFP fusion protein levels were examined by 
Western blot analysis. 
4.3.1 Increased expressions of fusion proteins 
At 30 hr post-transfection of fusion constructs into HeLa, the transfected cells 
were treated with 5 |aM of MG-132 for 16 hr, followed by Western blot analysis. As 
shown in Figure 4.12, virtually all of the GFP-BRE fusion proteins showed increased 
expression levels upon treatment with MG-132. 
7 4 
A) 
GFP LMP1 U L4 
, ^ " ~ C ~ M ^ ~ C ~ M G ~ "c MG C MG" • 
•: .‘•.vssjqppifti . . . ,.’..:、、：>«tftwyliDir’.“s：•；、:、:：減'iW丨：•-：^.、.； 
mmm ^mm •^ mm- ^trnm ^mmm. GAPDH 
B) 
kDa C1 C1V5 GS6 383 CA61 CA89 
C MG C MG C MG C MG C MG C MG yVB 
6 4 — " “ , 如 
49 - , J ^ ： - 醫 羞 / r ^ ^ l ^ f ^ ； ： ^ Anti-BRE 
8 2 - 一. 
_ — Anti-GFP 
6 4 - 势 • 
— • 遍. 
3 7 - _ 丨 義 丨 丨 丨 丨 丨 _ 響 _ 丨 , _ * 
•“ 一 GAPDH 
^mmmmm-
C) 
NB NB2 NBL N A61 NA89 
kDa C MG C MG C MG C MG C MG 蘭 
I I — - R E 
‘ 」 一 ： 一 ， 乂 養 “ ^ J ^ i a i B GAPDH 
Figure 4.12 Western blot of GFP-BRE fusions after MG-132 treatment 
Protein extracts form A) GFP, LMPl, LI, L4 transfectd cells; B) CI, C1V5, GS6, 
383, CA61, CA89,transfected cells; and C) NB, NB2，NBL, NA61, NA89 transfected 
cells were performed Western blot, probed with anti-BRE and anti-GFP, respectively. 
Loading of proteins were normalized by GAPDH proteins. 
Note: C: control treatment with DMSO; MG: 5 |.iM MG-132 treatment for overnight. 
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Changes of protein expression upon MG-132 treatment 
(detected by anti-GFP antibody) 
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Figure 4.13 Changes of fusion expression 
Upper: Bands of Western blot probed by anti-GFP antibody. 
Lower: Bands of Western blot probed by anti-BRE antibody or anti-LMP antibody 
(LMPl). 
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4.3.2 Subcellular localization of GFP-BRE fusion 
Since GFP-BRE LI behaved detectable fluorescent signals under microscopy, 
subcellular localization of GFP-BRE LI was monitored. Consistent with the previous 
results showed in Western blot, MG-132 treated cells showed brighter than the 
control cells (Figure 4.14A). 
Time course experiment was done to monitor the dynamic changes of fusion 
localization. The LI transfected cells appeared a GFP-BRE pattern of homogenous 
distribution in both of cytoplasm and nucleus, with mainly located to the latter. In the 
MG-132 treated cells, fusion proteins formed small particles at 6hr after MG-132 
treatment (Figure 4.14B). As prolong the treatment to 16 hr, the proteins were 
aggregated near the nucleus. However, in the GFP transfected cells, the aggregate of 
GFP was not observed (Figure 4.14). 
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A) 
DMSO MG132 • • • • 
B) 
DMSO MG-132 
Figure 4.14 Subcellular localization of GFP-BRE LI proteins. 
A) Low magnification (SOX) of DMSO or MG-132 treated GFP or LI transfected 
cells upon MG-132 treatment for 16h. 
B) High magnification (400X) of DMSO or MG-132 treated GFP or LI transfected 
cells upon MG-132 treatment. 
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To further investigate the properties of the other GFP fusion proteins, additional 
confocal experiments were performed. LMPl appeared in the cytoplasm, with a 
skeleton pattern. All of the C-terminal transfetants, CI and GS6, with and without V5 
epitope at the C-terminal of proteins respectively, as well as L4 and LI, with single 
and double ScFv linker respectively, showed mainly nucleus localization of 
GFP-BRE fusions. After overnight treatment with 5|.iM MG-132, these C-terminal 
GFP-BRE fusion proteins formed aggregation near or in the nucleus. In addition, the 
cytoplasm counterpart appeared weaker than the control groups. The cytoplasmic 
GFP-BRE fusion proteins translocated around or into the nucleus upon MG-132 
treatment (Figure 4.15). 
However, in the transfectants expression of N-terminal fusion proteins were 
found weaker than that of the C-terminal fusions. NB2 and NA61 showed lower 
green fluorescent signals than the others in Figure 4.15, which gave out less 





Figure 4.15 Confocal images of MG-132 treated transfectants 
Images were obtained by Confocal Laser Scanning Microscopy with 400X 
magnification. HeLa cells were transfecetd with the fusion constructs and seeded 
onto 12-well slides. Treatments of 5 |aM MG-132 were last for 16 hr. Left panels 
were DMSO treated transfectants. Right panels were MG-132 treated transfectants. 
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Chapter V Discussion 
5.1 Functional role of BRE in HCC 
The present study using liver-specific BRE transgenic mouse model has shown 
that the transgenic mice are significantly more prone to develop larger DEN-induced 
HCC than the non-transgenic littermates. Furthermore, the DEN-induced HCC also 
appeared up-regulation of the endogenous non-transgenic BRE. These findings 
experimentally confirm that the up-regulation of BRE previously observed in human 
HCC is not just an epiphenomal association, but an event of functional relevance to 
development of the carcinoma. As the present data have clearly shown that it is the 
growth rather than the initiation of the DEN-induced HCC that was enhanced by the 
BRE transgene, the functional effect of BRE up-regulation in human HCC can now 
be reasonably understood. That is, the over-expressed BRE protein may inhibit the 
apoptosis in the tumor cells. Taken together with the previous findings that this 
transgenic strain is also significantly more resistant to Fas-induced liver apoptosis 
(Chan et al., 2008), the consequence of BRE over-expression is likely to be the 
conferment of survival advantage to the carcinoma through anti-apoptotic activity of 
the protein. 
5.1.1 Stage model of carcinogenesis 
Initiation 
It is well known that DEN initiates mutation in hepatocytes by forming DNA 
adducts. Initiation requires further cell proliferations for the 'fixation' of this 
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mutagenic process (Pitot, 2001). Thus, cell proliferation is an important mechanistic 
aspect for both genotoxic and nongenotoxic carcinogens. It is essential to 
carcinogenesis for converting DNA adducts to mutation, and enhancing the mutation 
frequency by inducing errors in replication (Tomatis, 1993). 
It has been reported that a short-term effect of DEN treatment is up-regulation 
of H3-histone gene expression. Three days after DEN administration to C57BL/6J 
mice, H3-histone gene expression reached the first peak. Another 6 days later, a 
second peak of the gene expression with the same magnitude as the first occurred. 
DNA replication was found active 3 and 9 days after DEN treatment (Jin et al” 2005). 
Act as a proliferation marker, H3-histone revealed high cell proliferation in this early 
stage after DEN administration. DNA replication of mutated cells, to transmit the 
mutated message to the progeny, is essential for tumor formation (Fausto et al” 
1999). However, in my work, the expressions of BRE proteins stayed unchanged in 
the first week after DEN administration, suggesting that this protein is unlikely to be 
involved in the early events, such as enhanced cell proliferation, triggered by DEN. 
Promotion 
The stage of promotion may be modulated by the aging process (Van Duuren et 
al.’ 1975), and dietary and hormonal factors (Sivak, 1979). Estradiol is shown as a 
representative of endogenous hormones that are effective promoting agents. Both 
androgens and estrogens are effective promoting agents for the livers carcinogenesis 
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(Kemp a al, 1989; Taper, 1978). In the case of TTR-V5-BRE transgenic mouse 
model, over-expressed BRE proteins may function in the promotion process by 
interacting with other endogenous promoting agents. 
DEN-induced HCC was less efficient in female groups. In females, estrogen 
would inhibit the secretion of IL-6 from Kupffer cells exposed to necrotic 
hepatocytes and reduce circulating concentration of IL-6. Ablation of IL-6 protected 
male mice from DEN-induced HCC (Naugler et al., 2007). Only 10% of HCC 
incidence was observed in non-transgenic C57BL/6/129 background mouse (Maeda 
et al, 2005). In my study, higher HCC incidence of TTR-V5-BRE females (1/5) than 
the controls (1/12) indicated that over-expression of BRE might facilitate the 
DEN-induced HCCs in female mice. However, I could not make any statistical 
analysis, since it was only one HCC positive mouse in each group. Expanding the 
study by enlarging sample sizes was on-going in our lab. 
Progression 
The Bcl-2 family members, including pro-apoptotic and anti-apoptotic proteins, 
might play different roles in carcinogenesis. Pro-survival Bcl-2 acts as oncogene 
through inhibition of apoptosis to cause cancer in Bcl-2 transgenic mice (Cory et aL, 
2003). In the plasmacytomas devised from bcl-2 transgenic mice, the c-myc 
protooncogene, which promotes abnormal cell proliferation and tumorigenesis, was 
found rearranged. Bcl-2 could prolong the lifespan of mutated cells, allowing them to 
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accumulate additional oncogenic mutation, to promote neoplastic transformation 
(Zhivotovsky, 2006). As an anti-apoptotic protein (Li et al” 2004; Chan et al., 2008)， 
BRE proteins function similar to Bcl-2, to provide a survival advantage for those 
DEN-initiated mutated cells. 
Consistent with previous finding that BRE was over-expressed in human HCC 
by IHC assay (Chan et al, 2008), the DEN-induced mouse HCCs were also found 
over-expression of the endogenous BRE proteins by Western blot analysis. 
Over-expression of BRE may act as a pro-survival factor in the growth the tumor 
cells, resulting in larger tumor size in transgenic mice. 
5.1.2 Anti-apoptotic genes in cancer 
Another Bcl-2 family member, Bcl-w, is found frequently overexpressed in 
colorectal adenocarcinomas, but not adenomas. This protein appears to play a role in 
the progression from adenoma to adenocarcinoma in the colorectal epithelium 
(Wilson et al., 2000; Cory et al” 2003). In this progression stage, Bcl-w proteins may 
suppress tumor cell death by blocking activation of stress-activated protein kinase 
(SAPK)/c-Jun NH2-terminal kinase (INK) (Lee et al, 2003). 
Over-expression of inhibitor of apoptosis proteins (lAP) is involved in the 
resistance of some cancers to apoptosis (Ashkenazi and Herbst, 2008). Survivin is a 
member of lAP family. It functions in cell division and acts as a suppressor of 
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apoptosis. It is upregulated in human tumors (Pennati et al” 2008), and has been 
shown to directly inhibit activation of caspase-3 and -7 (Shin et al, 2001). 
5.1.3 Limitation of the study 
To directly cross-validate BRE up-regulation in DEN-induced HCC, 
immunohistochemical staining of the liver sections is the common method. However, 
our anti-BRE monoclonal antibody is a mouse antibody, which gave out a high 
staining background in the mouse liver tissue section. In addition, our homemade 
antibodies need further purification to optimize the staining. 
Further experiment should be done: isolate the hepatocarcinoma cells from the 
whole cells population derived from HCC livers, which also contained the infiltrating 
leukocytes; perform Western blot analysis to demonstrate the BRE protein levels in 
the hepatocarcinoma cells specifically. 
5.1.4 Conclusion 
In summary, the expression of BRE proteins was not affected in the early stage 
of DEN-induced tumorigenesis, but may function in stages of the promotion and 
progression. 
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5.2 Subcellular localization of BRE 
To investigate the function of BRE in cell line, I used the 9 full length GFP-BRE 
fusion proteins and the 4 mutants to visualize the proteins. The property of LI fusion 
was the best of all 9 GFP-BRE fusions, with highest expression level and fluorescent 
intensity. By tagging GFP to BRE, visible BRE protein was found in both nuclear and 
cytoplasmic compartments, with the former more prominently than the latter. 
GFP-BRE L1 fusion protein showed a pattern of homogenous distribution in HeLa 
cells. However, the 4 mutants with 61-86 residues or 89-114 residues deleted, which 
were highly conserved segment of BRE, could not improve the GFP fluorescence. 
Alteration of the localization of GFP-BRE fusion proteins and aggregates in or 
around the nucleus were observed after MG-132 treatments to the transfectents. 
Furthermore, MG-132, a proteasome inhibitor, enhanced the expression levels of the 
fusion proteins. 
5.2.1 Low expression of GFP-BRE fusions compare to LMPl 
Researchers successfully cloned the specific genes into GFP expression vectors. 
Those fusions demonstrated the localization properly and were fully functional 
(Cazzalini et al., 2004; Koroleva et al,’ 2005; Orban et al., 2008). However, in the 
case of GFP-BRE fusion protein, far lower florescence than the LMPl control fusion 
protein was found. To address this problem, three aspects of experiments were 
performed: 1. modification of fusion proteins to increase the stabilities of fusion 
proteins; 2. deletion of the conserved segments of BRE to see whether the mutants 
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could enhance the fluorescence and stability or not; 3. blocking the protein 
degradation by MG-132 to study stabilities of fusion proteins and the association 
between ubiquitins and BRE. 
1. Modification of fusion proteins 
BRE protein may interact with the GFP. It would render the fusion protein 
unstable or misfolding. The interference of protein size was ruled out from the 
reasons of instabilities, since that LMPl with same size expressed the green protein 
properly and showed high intensities of fluorescence. 
However, the intensities were not improved by the modification of the 
C-terminus of the fusion proteins. Two fusion proteins C1V5 and GS6 were 
generated by addition of V5 epitope to the C-terminus of CI and 383. These four 
fusions expressing full length of BRE proteins displayed nearly the same intensities 
in the flow cytometry analysis (Figure 4.2, 4.3). Blocking the C-terminus of the 
fusions could not rescue the fluorescent signals. 
Addition of the ScFv linker, which was a flexible (GGGGS)3 linker, between 
the GFP and BRE of CI fusion, made the fusion proteins L4 and LI, with one linker 
and double linkers, respectively. The ScFv linker was proved to increase the 
expression of recombinant fusion antibodyies (Trinh et al., 2004). LI and L4 showed 
high stabilities and intensities by Western blot and flow cytometry. 
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2. Mutants with two conserved segments deleted 
To investigate the causes of the low intensities of those GFP-BRE fusions, two 
specific regions of near N-terminal of BRE were deleted. However, the results were 
found even worse (Figure 4.8). According to the low expression of mutants, it may 
be resulted from the instabilities of the fusion proteins, which may encode a 
non-native form of BRE proteins. 
3. MG-132 treatment 
The ubiquitin-proteasome pathway is essential in the control of many processes 
in the cells, such as cell-cycle progression, signal transduction, transcriptional 
regulation, endocytosis and apoptosis (Hershko and Ciechanover, 1998). Conjugation 
of ubiquitin is known to be involved in signaling the conjugated proteins to 
proteasomal degradation (Pickart and Fushman, 2004). In the study of the expression 
of GFP-BRE fusions, the instabilities of the fusions may be rescued by inhibition of 
the ubiquitin-proteasomal degradation. 
In the ubiquitin proteaosome pathway, proteaosome is the executioner of the 
degradation. MG-132, a proteasome inhibitor, might block the degradation of the 
ubiquitinated proteins. Since ubiquitin plays a key role in the protein degradation 
process, treatment with MG-132 can show the pathway of ubiquitin specifically. 
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Interestingly, cells transfected with the above constructs after MG-132 treatment 
displayed enhanced protein stabilities by Western blot analysis. Aggregates were 
observed in or around the nucleus. It has been well demonstrated that proteasome 
inhibitors can induce apoptosis in cancer cells (Chauhan et al., 2005; Nawrocki et al, 
2005). Inhibition of the proteasome by MG-132 induces extensive cellular 
vacuolization, likely due to ER stress, and intracellular polyubiquitinated protein 
accumulation (Ding et al., 2007). Furthermore, treatment with MG-132 to U373 MG 
cells induced the formation of aggresomes and accumulation of ubiquitinated 
proteins (Hideori, 2002). It is likely that the aggregates of GFP-BRE fusions were the 
ubiquitinated proteins. Apart from the observations of the increased association of 
BRE and ubiquitinated proteins after death receptor stimulation (Li et al” 2004), and 
enhanced ubiquitin E3 ligase activity of the BRE contained complex BRCC (Dong et 
al., 2003)，here, the MG-132 treatment of transfectents revealed the correlation 
between BRE and ubiquitins. 
The aggregates only formed in the BRE-GFP fusion transfected cells but not the 
GFP or LMPl controls. The peri-nuclear aggregates may be the accumulation of the 
intracellular polyubiquitinated GFP-BRE fusion proteins (Hideori, 2002). At least in 
part, the ubiquitins were associated with BRE proteins. If BRE has a direct or 
indirect interaction with ubiquitins, upon apoptotic treatments of MG-132, BRE 
proteins may be ubiquitinated. Thus, its apoptotic function might be reduced via 
inhibition of ubiquitination for I kappa B and activation of NF-kappa B. 
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5.2.2 Additional study 
However, this finding was showed by the constructs encoded the GFP-BRE 
fusion proteins, which were not the native endogenous BRE proteins. Whether the 
GFP-BRE fusion proteins could reflect the endogenous ones should be further 
confirmed. Optimization of immunostaining using anti-BRE monoclonal antibody 
was ongoing. Immunostaining should be done to show the endogenous BRE proteins, 
to further relate the BRE proteins and ubiquitins. 
5.2.3 Conclusion 
GFP-BRE fusion proteins with visible fluorescence revealed the cytoplasmic and 
nuclear localization of BRE, with mainly in the nucleus. Upon treatment with 
MG-132 to the transfectents, the fusion proteins were prone to aggregate. 
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Appendixes 
I Raw data in the study 
1. Profiles of mice 
Breeder # � … Date of 
DOB Injection Date of 
4839 2006-11-26 2006-12-12 — breeder # q q q injection 
mouse # sex TG status 4885 2007-2-16 2007-3-2 
3998 M + mouse # sex TG status 
4000 M + ^ M -
3997 F + 4979 F -
399 9 F + F -
D J # Date of ^ . n Date of 
Breeder # ��� r . .. Breeder # … . 
DOB Injection DOB Injection 
4839 2007-1-17 2007-1-31 4831 2007-3-1 2007-3-15 
mouse # ^ TG status mouse # ^ TG status 
4944 M + M + 
4947 M + 4995 M -
4948 M + 4993 F -
4946 M - 4996 F -
4939 M - Date of 
4949 M - DOB Injection 
4943 F + 4839 2007-3-5 2007-3-19 
494 5 F + mouse # sex TG status 
Breeder # Date o f 6 8 2 7 M ？ 
DOB Injection 6828 F _ 
4 m 2007-2-13 2007-2-27 Date of 
—“—“~ Breeder # 
mouse # ^ TG status DOB Injection 
M + — 4884 2007-6-1 2007-6-15 — 
4972 M - mouse # sex TG status 
4973 M - ^ F -
4970 F - 6867 M + 
4974 F + 6868 M + 
4975 F - 6869 M + 
4976 F - 6870 F -
4977 F - 6871 M + 
4978 F - 6872 M -
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2. Densities of Western Blot bands (Up-regulation of endogenous BRE proteins, 
Table 3.3) 
Number EndogenousBRE GapDH Nor endo Upregulation 
4 9 4 4 N ^ R55 OJ07 8.07 
4944T Q ^ 
4947N O ^ R ^ 0 0 8 ^ 
4947T Q ^ 135 
4948N ^ \3\ OOO ^ 
4948T 
^4971N ^ L30 0^ 017 JIJl 
497 I T Q ^ 
4997N ^ ^ 0^23 W S 
4997T ^ 1.74 0.22 
3998N ^ M I T I 
T 。 3998T 0.36 1.71 0.21 
TG +ve 
4000N 0.16 1.19 0 . 1 3 8.18 
4000T ^ O M 
6827N ^ ^ TT2 
6827T Q ^ Q ^ 
6867N ^ L58 O!O6 W S 
6867T Q ^ 
6868N 0 3 8 ^ L0~2 
6868T ^ 
6869N ^ O M 
6869T Q J 2 ^ 
6871N ^ iTm o l ^ L47 
6871T ^ Q M 
4939N ^ L65 ^ TT9 
4939T 
4946N ITN R ^ U L 
4946T ^ ^ 
4949N ^ U 2 T JS 
4949T U 5 
4972N 0 ? ^ ^ IL43 ^ 
4972T 1.18 1.28 0 . 9 3 
TO -ve 
4973N 0.26 0.75 0 . 3 5 2,24 
4973T 
4981N 0 5 5 R ^ C L ^ 
4981T I M 
4995N ^ ^ ^ 
4995T \ M Q ^ I M 
6872N U S ^ L ^ 
6872T IM 
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3. Intensities of GFP-positive cells (Figure 4.3) 
Name GeoMean of Ml (4 independent experiments) 
2Q080328_1 20080328_2 2QQ8Q221 20080303 肌 SD 
Neg-ctl n ^ 14.58 12.78 9.85 12.11 1.78 
GFP 639.04 433.74 845 372.38 572.54 214.47 
LMPl 197.33 211.36 211.69 179.13 55.73 
30.03 33.76 25A4 31.90 5.72 
C1V5 30.96 31.91 33^ 25M 30.46 3.81 
GS6 30.76 37.48 41.37 29.13 34.69 5.74 
GS383 3 5 . ^ 38.5^ 27.8 33.42 
81.35 104.1 121.64 65.14 93.06 24.87 
L4 44.16" 65.43— 60.06 36.84 51.62 ~T3.37 
NB 23.07- 23.24— 27.05 21.2 23.64 2.45 
NB2 一 2 2 i r 2 l i r 23 .4^ 19.33 21.59 —1.72 
NBL 2 6 ^ 25.78 21.42 24.83 2.28 
CA61 2 6 ^ 27.19 3 1 ^ 27.10 3.38 
CA89 23.95 24.06 1 9 ^ 24.47 4.40 
NA61 — 2 i y 23.61 27.06 18.46 22.58 3.65 
NA89 21.57 14.86 21.01 16.69 18.53 3.28 
4. Densities of Western B ot bands (Figure 4.5) 
Relative 
Name GSBRE GAPDH Normalized degree 
GFP 0 . 8 5 0 3 6 5 4 ‘ 4.055271252 0 . 2 0 9 6 9 3 ^ 6.99 
LMPl 0.711874073 4.454916223 0.159795165 5.33 
CI — 0.21663943 4.531627166 0.047806102 1.59 
C1V5 0.402900929 4.375721263 0.092076461 3.07 
GS6 — 0 . 4 4 0 4 6 2 6 ^ 4.757355687 0 . 0 9 2 5 8 5 ^ 3.09 
383 ~ 0 . 2 1 5 8 5 9 7 ^ 4.421051011 0 . 0 4 8 8 2 5 ^ 1.63 
1L1 — 0.3075681^ 4 . 3 5 0 0 3 9 ^ 0.010104m 2.36 
M 0.173407123 4.199685253 0.041290505 1.38 
NB 0.393416685 3.804291097 0.103413928 3.45 
"NB2 0.340042619 3.729094944 0.091186367 3.04 
NBL 0.125666908 3.875224744 0.032428289 1.08 
1 0 4 
5. Densities of Western Blot bands (Figure4.3) 
G F P \ 
Name fusions GAPDH Normalized 
LMPl 6.4130237 2.8683280 2.235805?" 
CI 1.6185435 2.6884523 0.6020354 
C1V5 1 . 5 5 2 0 4 ^ 2.2184032 0.6996216 
GS6 2.0926682 1.6988736 1.2317975 
383 2.3092240 2.2344583 1.0334603" 
LI 4 . 2 7 2 2 5 ^ 1.8682718 2.2867407 
L4 3.4659874 2.2694300 1.5272502 
NB 0.354878^ 2.6039423 0.1362851 
NB2 ~ ~ 0.2263540 2.9600812 0.0764691 
NBLL 2.8261978 2.6441392 1.0688536 
6. Densities of Western Blot bands 
GFP-BRE 
Name fusions GAPDH Normalized 
CI 5.3152201— 4.5316272 1.1729165 
C 1 V 5 ~ 5.0283716 4.37572lT 1.1491526 
G S 6 ~ 4.138127^ 4.7573557 0.869837T 
383 4.1165101— 4.4210510 0.9311157 
LI 4.9482973 4.3500400 1.1375291 
L4 3.7064633 4.1996853" 0.8825574 
NB 2.6379206 3.8042911 0.6934066 
N B 2 ~ ~ 1.3149639 3.7290949^ 0.3526228 
NBLL 1.6535267 3.8752247 0.42669 i T 
Densities of WB bands of Figure. 
Mutants bre g ^ 
1.593458 0.573583 
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7. CD45 IHC of Negative control and #6869 liver section 
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8. Description of Materials 
1) Usage of Primers 
LMPH3/LMPBam3 for PGR LMPl 
GS5/GS3 for PGR GS6 
GS5/Bre383BamHI for PGR 383 
BreCHindIII/GS3 for PGR C1V5 
BreCHindIII/Bre383BamHI for PGR CI 
N3BGLII/N3HINDIII for PGR NB2 
Bre5'NHindIII/N3HINDIII for PGR NB 
Bre603/Bre875/60LINK87 for PGR BREA61-86 
Bre883/Brell4/88LINK114 for PGR BREA88-114 
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II Abstracts of publication 
1. Oncogene. 2008 Feb 21;27(9):1208-17. 
BRE is an antiapoptotic protein in vivo and overexpressed in human 
hepatocellular carcinoma. 
Chan BC, Ching AK, To KF, Leung JC, Chen S，Li Q, Lai PB, Tang NL, Shaw PC, 
Chan JY, James AE, Lai KN, Lim PL, Lee KK, Chui YL. 
Clinical Immunology Unit and Sir YK Pao Centre for Cancer, Prince of Wales 
Hospital, Chinese University of Hong Kong, Shatin，NT, Hong Kong SAR, China. 
BRE binds to the cytoplasmic domains of tumor necrosis factor receptor-1 and Fas, 
and in cell lines can attenuate death receptor-initiated apoptosis by inhibiting 
t-BID-induced activation of the mitochondrial apoptotic pathway. Overexpression of 
BRE by transfection can also attenuate intrinsic apoptosis and promote growth of the 
transfected Lewis lung carcinoma line in mice. There is, however, a complete lack of 
in vivo data about the protein. Here, we report that by using our BRE-specific 
monoclonal antibody on the immunohistochemistry of 123 specimens of human 
hepatocellular carcinoma (HCC), significant differences in BRE expression levels 
between the paired tumoral and non-tumoral regions (P<2.2e-16) were found. 
Marked overexpression of BRE was detected in majority of the tumors, whereas 
most non-tumoral regions expressed the same low level of the protein as in normal 
livers. To investigate whether BRE overexpression could promote cell survival in 
vivo, liver-specific transgenic BRE mice were generated and found to be 
significantly resistant to Fas-mediated lethal hepatic apoptosis. The transgenic model 
also revealed post-transcriptional regulation of Bre level in the liver, which was not 
observed in HCC and non-HCC cell lines. Indeed, all cell lines analysed express high 
levels of BRE. In conclusion, BRE is antiapoptotic in vivo, and may promote 
tumorigenesis when overexpressed. 
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2. AACR Centennial Conference Translational Cancer Medicine 2008: 
Cancer Clinical Trials and Personalized Medicine 
Hyatt Regency Monterey, Monterey, California July 20 - 23，2008 
An anti-apoptotic protein, BRE, promotes growth of chemically-induced mouse 
hepatocellular carcinoma 
Shuyan Chen, Arthur Kar-Keung Ching, Dewi Kenneth Rowlands, Anthony Edward 
JAMES, Yiu-Loon Chui. 
Here we report further our investigation of the role of BRE in HCC. HCC was 
chemically-induced in the transgenic (TTR-V5-BRE) and non-transgenic littermates, 
bred with C57BL/6, by intraperitoneal injection of diethylnitosamine (DEN) at 15 
days postnatally. At 8 months after injection, the mice were sacrificed, and livers 
collected for determination of tumor number and maximal size, and for 
immunohistochemistry. Parts of each liver sample were also dissected visually into 
tumor and adjacent normal portions for Western Blot analysis of BRE expression. By 
comparison between the DEN-treated male transgenic mice (n=12) and 
non-transgenic littermate controls (n=8), we observed significantly increased tumor 
size shown by the former (p=0.049，Exact Wilcoxon Rank Sum test), with the 
median tumor size 2-fold larger than the latter. There was, however, no statistically 
significant difference between tumor numbers of the two groups. Female C57BL/6 
mice are known to be less sensitive to DEN-treated carcinogenesis. We observed 
only 8.3% of the female non-transgenic littermates (n=12) developed DEN-induced 
HCCs, whereas 20% of female transgenic mice (n=5) developed the malignancy. 
For the paired tumoral and normal liver tissues, increased expression of the mouse 
endogenous BRE was detected in the former by Western Blot analysis. This 
observation is comparable with the up-regulation of BRE in human H C C . � We 
further demonstrated that DEN administration has no direct effect on BRE 
expression, as injection of the chemical did not result in any change in the protein 
expression level in the livers of 15-day old infant mice or 6-8 weeks adult mice in at 
least the first week post-injection. 
We have previously reported that BRE is highly expressed in lymphoid organs, such 
as spleen and thymus, suggesting that lymphocytes may be BRE-posi t ive .� As 
DEN-induced HCC is often accompanied by various degrees of leukocytic 
infiltration, contribution of these infiltrating cells to the observation of BRE protein 
up-regulation in the liver tumors was studied using common leukocyte antigen CD45 
immunohistochemitry staining. No correlation between incidence of infiltration and 
the up-regulation of BRE was found. 
Taken together, our results suggest that BRE promotes growth, but not induction of 
hepatocellular carcinoma. 
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